

Review

Not peer-reviewed version

---

# SMI-Capsular Fibrosis and Biofilm Dynamics: Molecular Mechanisms, Clinical Implications, and Antimicrobial Approaches

---

[Ines Schoberleitner](#) , [Michaela Lackner](#) , [Debora C. Coraca-Huber](#) , [Angela Augustin](#) , Anja Imsirovic ,  
[Stephan Sigl](#) , [Dolores Wolfram](#) \*

Posted Date: 10 October 2024

doi: 10.20944/preprints202410.0831.v1

Keywords: silicone mammary implants (SMI); capsular fibrosis; biofilm formation; antimicrobial strategies; foreign body response (FBR); implant surface modification; microbial adhesion; fibrotic response; antimicrobial-impregnated materials; surface topography



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

# SMI-Capsular Fibrosis and Biofilm Dynamics: Molecular Mechanisms, Clinical Implications, and Antimicrobial Approaches

Ines Schoberleitner <sup>1,2</sup>, Michaela Lackner <sup>3</sup>, Débora C. Coraça-Huber <sup>4</sup>, Angela Augustin <sup>5</sup>, Anja Imsirovic <sup>2</sup>, Stephan Sigl <sup>2</sup> and Dolores Wolfram <sup>2,\*</sup>

<sup>1</sup> Institute of Pathology, Neuropathology and Molecular Pathology, Medical University of Innsbruck, Müllerstraße 44, 6020 Innsbruck, Austria

<sup>2</sup> Department of Plastic, Reconstructive and Aesthetic Surgery, Medical University of Innsbruck, 6020 Innsbruck, Austria

<sup>3</sup> Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, 6020 Innsbruck, Austria

<sup>4</sup> Department of Orthopedics and Traumatology, BIOFILM Lab, Medical University of Innsbruck, 6020 Innsbruck, Austria

<sup>5</sup> Department of Obstetrics and Gynecology, Medical University of Innsbruck, 6020 Innsbruck, Austria

\* Correspondence: dolores.wolfram@i-med.ac.at

**Abstract:** Silicone mammary implants (SMIs) frequently result in capsular fibrosis, which is marked by the overproduction of fibrous tissue surrounding the implant. This review provides a detailed examination of the molecular and immunological mechanisms driving capsular fibrosis, focusing on the role of foreign body responses (FBR) and microbial biofilm formation. We investigate how microbial adhesion to implant surfaces and biofilm development contribute to persistent inflammation and fibrotic responses. The review critically evaluates antimicrobial strategies, including preoperative antiseptic protocols and antimicrobial-impregnated materials, designed to mitigate infection and biofilm-related complications. Additionally, advancements in material science, such as surface modifications and antibiotic-impregnated meshes, are discussed for their potential to reduce capsular fibrosis and prevent contracture of the capsule. By integrating molecular insights with clinical applications, this review aims to elucidate the current understanding of SMI-related fibrotic responses and highlight knowledge gaps. The synthesis of these findings aims to guide future research directions of improved antimicrobial interventions and implant materials, ultimately advancing the management of capsular fibrosis and enhancing patient outcomes.

**Keywords:** silicone mammary implants (SMI); capsular fibrosis; biofilm formation; antimicrobial strategies; foreign body response (FBR); implant surface modification; microbial adhesion; fibrotic response; antimicrobial-impregnated materials; surface topography

## 1. Introduction

The body's natural wound-healing process plays a central role in medical implant outcomes [1], particularly in individuals receiving silicone mammary implants (SMI). When an SMI is placed, the body initiates a wound-healing response that can lead to implant encapsulation and forming a fibrous capsule around the implant, a condition known as capsular fibrosis [1,2]. While this is part of the body's attempt to isolate the foreign object and restore tissue integrity, excessive fibrosis can result in complications such as pain, implant deformation, and reduced mobility [3,4]. Moreover, the interaction between biofilm formation on the implant surface and the wound-healing process is believed to exacerbate fibrotic responses [5]. Understanding the fundamentals of wound healing is essential for developing strategies to reduce capsular fibrosis and effectively manage biofilm dynamics in individuals undergoing SMI implantation.

### 1.1. Foundations of Wound Healing: Implications for Health and Recovery

Wound healing is a crucial biological process fundamental for restoring the integrity and functionality of damaged tissues. It involves a complex series of overlapping phases: hemostasis,

inflammation, proliferation, and remodeling, which are aimed at repairing physical damage, preventing complications, and ensuring overall health and recovery.

Hemostasis is the initial response to tissue damage. When the skin is injured, blood vessels constrict to reduce blood loss, followed by the activation of platelets that form a clot. This clot acts as a temporary barrier against pathogens and provides a scaffold for incoming cells. Platelets release growth factors and cytokines that signal the subsequent phases of healing responses [6–8]. The clot is eventually reinforced by the conversion of fibrinogen into fibrin, creating a stable thrombus that aids in tissue repair [6–8].

The next phase, inflammation, begins shortly after hemostasis. This phase is marked by the recruitment of immune cells to the wound site to prevent infection and clear debris. Neutrophils are the first responders, arriving within the first 24 hours to combat pathogens and release enzymes that help degrade damaged tissue. They are followed by macrophages, which continue the process of debris removal and release cytokines that modulate the inflammatory response [9–12]. These cells also produce matrix metalloproteinases (MMPs) that degrade extracellular matrix (ECM) components, preparing the wound bed for new tissue formation [10,13]. Macrophages help transition from the inflammatory to the proliferative phase by resolving inflammation and releasing factors that promote tissue repair [14,15].

During the proliferative phase, new tissue is formed to restore the wound area. This includes fibroblast proliferation and ECM deposition, which provide structural support for new tissue. Fibroblasts produce collagen and other ECM components, while endothelial cells contribute to angiogenesis, forming new blood vessels to supply nutrients and oxygen to the growing tissue [16–19]. Epithelial cells migrate across the wound to re-establish the skin barrier. This phase also involves wound contraction, driven by myofibroblasts, which helps reduce the wound's surface area [20–26].

The final phase, remodeling, focuses on strengthening and refining the newly formed tissue. During remodeling, collagen fibers are realigned and cross-linked to enhance tensile strength. The ECM undergoes continual remodeling by MMPs and their inhibitors, leading to the maturation of the wound tissue [16,24,27–30]. This phase can last for months to years, during which time the appearance and functionality of the tissue improve as scar tissue is gradually replaced with more normal tissue architecture.

Effective wound healing is essential for repairing the skin's physical structure and preventing complications such as chronic wounds and pathological scarring, which can lead to persistent pain, impaired function, and increased healthcare costs [9,15]. By ensuring that damaged tissues are effectively repaired, wound healing reduces the risk of further tissue damage and supports the restoration of normal tissue function, ultimately improving outcomes and quality of life for patients.

A key component of wound healing is the prevention of infection. Infections are a common complication in wound care and can significantly impede the healing process, potentially leading to severe health issues [15,31–33]. Effective wound healing involves forming a protective barrier through coagulation and subsequent epithelialization, which helps prevent pathogen entry and supports pathogen clearance. This barrier is crucial for minimizing infection risk and promoting a safer, more rapid recovery [15,34].

Another important aspect of effective wound healing is its impact on scar formation. Optimal healing process can reduce excessive scarring, which is vital for both aesthetic and functional reasons [6,7]. Excessive scarring, including hypertrophic scars or keloids, can adversely affect the appearance and function of the repaired tissue. Minimizing scar formation enhances cosmetic outcomes and preserves skin texture and elasticity, which is particularly valuable in surgical and cosmetic procedures [35,36].

Wound healing is also essential for promoting functional recovery. Restoring normal tissue function is crucial for the recovery of movement, sensation, and overall functionality of the affected area [10,37]. In clinical settings, such as after surgery or injury, effective healing ensures that the repaired tissue regains its full functionality, which is critical for enabling patients to return to their normal activities and achieve successful rehabilitation [11].

The overall impact of wound healing extends beyond immediate repair. Chronic wounds or inadequate healing can lead to systemic complications, such as prolonged inflammation, metabolic disturbances, and increased susceptibility to further health issues [29]. Effective wound healing supports overall health by mitigating these risks and reducing the burden on the healthcare system. Promoting rapid and effective repair helps prevent the escalation of health problems and contributes to a more efficient, cost-effective healthcare approach [30].

Advancements in the molecular understanding of wound healing have significantly improved how we approach and manage wounds, leading to notable enhancements in clinical outcomes [20,38]. Key developments include the elucidation of cellular signaling pathways, such as those involving growth factors like Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor-beta (TGF- $\beta$ ), as well as cytokines like Interleukin-1 (IL-1) and Tumor Necrosis Factor-alpha (TNF- $\alpha$ ) [9,39–41]. During wound healing, these pathways regulate crucial processes such as cell proliferation, migration, and differentiation. Understanding these mechanisms has enabled the development of targeted therapies that modulate these pathways to improve healing outcomes.

Research into stem cells has revealed their critical role in wound repair. Mesenchymal stem cells (MSCs) and epithelial stem cells have shown the ability to differentiate into various cell types necessary for tissue regeneration and to secrete factors that promote healing [31]. These advances underscore the potential of stem cell therapies to accelerate wound repair and enhance recovery.

Further progress in understanding the molecular basis of fibrosis has illuminated how excessive scar tissue forms and persists. Key players in this process include fibroblasts, myofibroblasts, and ECM components along with their regulatory proteins [15,33,34]. This knowledge has facilitated the development of strategies to manage and mitigate excessive scar formation, improving the quality of wound healing.

Recent advancements have provided insights into the mechanisms of inflammation resolution, elucidating how the inflammatory response transitions into the proliferative phase of healing [6]. This includes understanding the roles of anti-inflammatory cytokines and the resolution of inflammatory cell infiltration, which has refined approaches to managing chronic inflammation and supporting effective tissue repair.

Genetic and epigenetic research has identified specific genes and regulatory mechanisms influencing wound healing. Changes in gene expression during various healing phases, along with epigenetic modifications affecting cell behavior, have enabled more personalized treatment approaches [7]. Tailoring interventions based on individual genetic profiles can optimize therapeutic efficacy and improve patient outcomes.

Understanding ECM composition and remodeling has also progressed, revealing how the ECM supports cell migration and tissue repair [14,35,36]. These insights have led to the development of novel biomaterials designed to mimic the natural matrix, enhancing the healing environment and promoting better wound repair.

The field has seen significant advancements with the development of biomaterials such as hydrogels, scaffolds, and nanomaterials. These materials interact with cellular and molecular processes to deliver growth factors, support cell growth, and modulate the healing environment, improving the management of complex wounds [10,11].

Molecular diagnostics and personalized medicine have advanced with the use of biomarkers and genomic profiling, enabling more tailored approaches to wound management [31,42]. This personalization allows for the customization of treatments based on genetic and molecular profiles, enhancing the efficacy of interventions and improving patient outcomes.

Finally, research into immune system interactions with wound healing processes has provided valuable insights into the roles of various immune cells in tissue repair and remodeling [14]. Understanding these interactions has improved the management of inflammatory responses and supported effective healing.



1.2. Wound Healing Dynamics, Microbial Biofilms, and Fibrotic Responses in Silicone Mammary Implants

Silicone mammary implants (SMIs) have played a pivotal role in breast surgery since their inception in the early 1960s [43]. Initially developed to meet the demand for cosmetic breast augmentation, these implants quickly became a cornerstone in reconstructive surgery for post-mastectomy patients [44].

Upon the implantation of SMIs, the body initiates an immediate wound response characterized by activation of the innate immune system. Immune cells such as neutrophils, macrophages, and dendritic cells are recruited to the site due to microbial contamination, implant shedding, silicone bleeding, and protein adsorption onto the implant surface [2,45–50]. Table 1 provides a comparative overview of these physiological mechanisms and their roles in the wound response to silicone mammary implants.

**Table 1.** Key physiological processes and their impact on wound healing around silicone mammary implants.

Biological Mechanisms	Wound Healing Dynamics	Fibrotic Responses in SMI
Pathophysiological Process	Restoration of tissue integrity and function through hemostasis, inflammation, proliferation, and remodeling.	Formation of a fibrous capsule around implants due to inflammatory response and biofilm formation.
Initial Response	Hemostasis: Constriction of blood vessels, platelet activation, clot formation to prevent blood loss and provide a scaffold for healing.	Immediate Immune Response: Activation of innate immune system, recruitment of immune cells (neutrophils, macrophages) due to microbial contamination and protein adsorption.
Molecular Components	Platelets, Fibrinogen, Fibrin: Form a clot that acts as a barrier and temporary scaffold.	Microorganisms, Proteins: Microbial biofilm formation on the implant surface, leading to persistent immune stimulation.
Inflammatory Phase	Neutrophils and Macrophages: Clear debris, combat infection, release cytokines and MMPs to modulate the inflammatory response.	Chronic Inflammation: Persistent inflammation due to biofilm, leading to prolonged immune response and ongoing ECM remodeling.
Proliferation Phase	Fibroblast Proliferation, ECM Deposition, Angiogenesis, Epithelialization: Formation of new tissue, collagen production, and blood vessel formation.	Fibrous Capsule Formation: Collagen and ECM deposition around the implant, leading to capsule formation.
Remodeling Phase	Collagen Realignment, Cross-Linking, Continual ECM Remodeling: Strengthening of new tissue and refinement of the wound architecture.	Capsular Contracture: Excessive collagen deposition and ECM remodeling leading to a contracted and thickened fibrous capsule.
Impact on Healing	Prevention of Infection, Scar Formation: Effective healing reduces infection risk, minimizes scar formation, and restores tissue function.	Infection Risk: Biofilms create a persistent infection risk that complicates healing and exacerbates fibrosis.

As the healing progresses, the body forms a fibrous capsule around the implant to isolate the foreign material. This involves the deposition of ECM components such as collagen, leading to the development of a fibrous capsule [46,47,49,51,52]. The extent of fibrosis around silicone mammary implants is shaped by both the initial inflammatory response and the length of chronic inflammation.

Persistent inflammation, caused by continuous protein adhesion to the SMI surface and ongoing microbial infiltration, can result in excessive ECM remodeling, increased collagen deposition, and subsequent contracture of the fibrous capsule.

Microbial biofilms that form on the implant surface can persistently stimulate the immune system, leading to prolonged inflammation [53–55]. This persistent inflammation is a major factor contributing to excessive ECM remodeling and increased collagen deposition, which exacerbates fibrosis [50,55–57]. The continued presence of biofilms intensifies the inflammatory process and promotes the formation of a thick, contracted capsule, ultimately resulting in capsular contracture [58–60].

The impact of antimicrobial agents on fibrosis around silicone mammary implants is significant in managing and mitigating fibrotic responses. Antimicrobial treatments, including the use of antimicrobial coatings on implants and systemic antibiotics, aim to prevent or reduce microbial biofilm formation and associated chronic inflammation [61–65].

In examining the management of fibrosis, this review explores the intricate biological pathways involved in the formation and remodeling of fibrous capsules around SMIs. Special attention will be given to how chronic inflammation and excessive ECM remodeling contribute to fibrosis and capsular contracture.

The role of microbial transmission, particularly the formation of biofilms, will be a central focus. Biofilms on implant surfaces can lead to persistent stimulation of the immune system, resulting in prolonged inflammation and exacerbated fibrotic responses. Understanding the relationship between microbial contamination, biofilm formation, and chronic inflammation is essential for developing effective strategies to enhance implant biocompatibility and reduce complications.

Antimicrobial strategies are crucial in controlling infections and improving implant outcomes. Our work assesses current antimicrobial approaches, including antimicrobial coatings and systemic antibiotics, evaluating their effectiveness in preventing or reducing biofilm formation and managing infection. These strategies are vital for reducing the risk of complications and enhancing the long-term success of implants.

Additionally, we discuss novel antiseptic therapies, which offer new opportunities for improving wound healing and reducing infection rates. By examining recent advancements in antiseptic agents, including their mechanisms of action and clinical applications, we aim to identify innovative approaches for enhancing the safety and efficacy of silicone mammary implants.

Through a comprehensive overview of these topics, we want to provide valuable insights into the latest advancements in fibrosis management, infection prevention, and antiseptic therapies. By connecting molecular research with practical clinical applications, we aspire to improve our understanding of these critical factors and their implications in patient care.

## **2. From Wound to Peri-SMI Capsular Fibrosis**

Fibrosis is a pathological condition characterized by the excessive accumulation of ECM components, particularly collagen, leading to scar tissue formation and impaired tissue function [2]. This process is often a consequence of chronic inflammation and injury, where normal wound-healing responses become dysregulated, resulting in persistent fibrosis [2,45,66,67].

### *2.1. Immediate Inflammatory Response and Early Fibrosis*

#### **Acute Inflammatory Response**

Upon silicone implant placement, the body's initial reaction involves an acute inflammatory response. The implant's surface, whether smooth or textured, acts as a foreign body, triggering a cascade of immune responses. Macrophages are among the first responders, recognizing and attempting to engulf the silicone material. This process, often leading to impaired phagocytosis, results in prolonged inflammation [2,45]. Macrophages release a range of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF- $\alpha$ ), interleukin-1 $\beta$  (IL-1 $\beta$ ), and interleukin-6 (IL-6), which recruit additional immune cells and activate fibroblasts [12,45,66,68,69].

Fibroblasts, in response to inflammatory cytokines, transition from a quiescent to an activated state, characterized by the secretion of matrix metalloproteinases (MMPs) and cytokines that facilitate tissue remodeling [2,66,70]. Early fibrosis begins with the accumulation of fibroblasts around the implant, contributing to the formation of a provisional matrix. This matrix, rich in collagen type III, serves as a scaffold for subsequent repair processes [52].

### Early Fibrotic Changes

The transition from acute inflammation to early fibrosis is marked by the differentiation of fibroblasts into myofibroblasts [71,72], cells with contractile properties due to the expression of  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA) [1,23,73]. These myofibroblasts are integral to the formation of the fibrous capsule, exerting mechanical forces that influence the organization of the ECM [1]. The initial fibrotic response involves a temporary increase in ECM components such as collagen and fibronectin, which are later replaced by more stable collagen types I and III as the fibrosis matures [46,74–77].

### Molecular Signaling Pathways

Key signaling pathways driving early fibrosis include the transforming growth factor-beta (TGF- $\beta$ ) pathway, which plays a crucial role in fibroblast activation and myofibroblast differentiation [78–80]. TGF- $\beta$  stimulates fibroblasts to produce ECM proteins and to adopt a contractile phenotype. Additionally, the nuclear factor-kappa B (NF- $\kappa$ B) pathway is activated in response to inflammatory cytokines, further promoting fibroblast proliferation and ECM deposition [81].

## 2.2. Chronic Inflammation and Capsular Contracture

### Chronic Inflammatory Response

As the inflammatory response persists, chronic inflammation ensues. This phase is characterized by the continued presence of immune cells, particularly macrophages and T cells, which sustain the inflammatory milieu [45]. Macrophages in this stage often differentiate into foreign body giant cells (FBGCs), which are involved in chronic inflammation and fibrosis [69,82–84]. Pro-inflammatory cytokines such as TNF- $\alpha$  and IL-1 $\beta$  continue to drive fibroblast activity and ECM deposition [71,72].

### Capsular Contracture Formation

The progression to capsular contracture involves a shift from initial fibrosis to a more organized and denser fibrous capsule. This process is marked by increased collagen deposition, particularly collagen type I, and the development of a rigid fibrotic capsule around the implant [76,85]. The contractile activity of myofibroblasts, driven by sustained TGF- $\beta$  signaling [40,79], contributes significantly to capsule contraction and rigidity [23,29,86].

The Baker classification system, which assesses the severity of capsular contracture, reflects the extent of fibrotic encapsulation and its impact on implant aesthetics and function [87–89]. This system categorizes capsular contracture into four distinct grades, reflecting the degree of fibrous tissue formation around the implant and its impact on both the aesthetics and functionality of the breast. In Grade I, the breast appears soft and natural, indicating minimal to no contracture. Grade II describes a breast that is slightly firm but still looks normal, suggesting some fibrous encapsulation is present. Moving to Grade III, the breast becomes firm and may appear abnormal, indicating a significant degree of contracture that can affect the shape and overall appearance. Finally, Grade IV signifies a hard breast with a distorted implant, reflecting severe capsular contracture that often necessitates surgical intervention [87–89].

The chronic inflammation and continuous fibroblast activation lead to a thickened capsule, which can impact the implant's position and patient comfort [4,90].

### Molecular Signaling Pathways

In chronic inflammation, the persistent activation of TGF- $\beta$  and NF- $\kappa$ B pathways continues to drive fibroblast activity and ECM remodeling [40,78,79,91]. TGF- $\beta$  signaling enhances the synthesis of collagen and other ECM proteins [78,79], while NF- $\kappa$ B promotes the expression of inflammatory

cytokines and ECM-degrading enzymes like MMPs [81,92]. The interplay between these pathways results in a fibrotic environment that sustains capsule formation and contracture.

### Immune Cell Interactions

T cells, particularly CD4<sup>+</sup> T helper cells, play a crucial role in chronic inflammation[93]. A predominance of T helper 2 (Th2) and T helper 17 (Th17) cells is associated with increased fibrosis, as these cells secrete cytokines that promote fibrotic responses [94,95]. Regulatory T cells (Tregs) also influence fibrosis, with their presence often inversely proportional to the severity of capsular contracture [93,96,97]. Tregs can modulate the immune response and influence the fibrotic process, though their role can be complex and context-dependent[47].


### S100 Proteins on Inflammation and Fibrosis

S100 proteins are a family of calcium-binding proteins that are implicated in various inflammatory and fibrotic processes[98–100]. They are involved in regulating cell motility, differentiation, and inflammatory responses [99,100]. S100A8 and S100A9, for instance, are released by activated macrophages and are known to participate in the inflammatory response by promoting neutrophil chemotaxis and activating other inflammatory cells [100,101].

In the context of silicone implants, S100 proteins can contribute to the pathogenesis of capsular fibrosis. Elevated levels of S100A8 and S100A9 have been associated with chronic inflammation and fibrosis in various tissues, including those surrounding implants [46,47,101]. These proteins interact with receptor RAGE (receptor for advanced glycation end-products) on immune cells, modulating cytokine release and fibroblast activation [101,102]. Their presence in the fibrotic capsule can exacerbate inflammatory responses and promote fibroblast proliferation and ECM deposition, thereby influencing the severity of capsular fibrosis [100].

Figure 1 illustrates the complex sequence of events leading from the immediate inflammatory response to the development of fibrosis and eventual capsular contracture following SMI insertion. This figure emphasizes how initial acute inflammation, triggered by tissue damage and the immune system's response to the foreign body, progresses to chronic inflammation and fibrosis. Over time, these processes contribute to the formation of a dense, fibrotic capsule around the implant, characterized by increased ECM deposition and the activation of fibroblasts and myofibroblasts, ultimately leading to capsular contracture.






**Figure 1.** Stages of the inflammatory and fibrotic response SMI insertion, illustrating the transition from immediate post-implantation inflammation to long-term fibrosis and implant encapsulation, with a detailed schematic of the cellular and molecular events driving these processes. Schematic representation of the cellular and molecular events involved in the inflammatory and fibrotic processes: (1.) *Lymphocyte Activation*: CD4<sup>+</sup> T cells are activated by dendritic cells (DC) presenting antigens through major histocompatibility complex (MHC) molecules. Heat shock proteins (HSP60) and other danger-associated molecular patterns (DAMPs) interact with pattern recognition receptors (PRR) and toll-like receptors (TLR), initiating the immune response. (2.) *Th1/Th17 Immune Response*: Activated T cells differentiate into Th1 and Th17 subsets, secreting pro-inflammatory cytokines (IL-1 $\beta$ , IFN- $\gamma$ , TNF- $\alpha$ , IL-17), which drive the inflammatory response while suppressing regulatory T cells (Treg). (3.) *Macrophage Activation*: M1 macrophages, stimulated by the inflammatory environment, contribute to chronic inflammation. Over time, there may be a transition to M2 macrophages, associated with tissue repair and fibrosis. (4.) *Fibrogenesis*: Myofibroblasts arise from fibroblasts under the influence of cytokines like TGF- $\beta$ , leading to the production of ECM components and the development of fibrotic tissue. (5.) *ECM Remodeling*: The ECM undergoes significant changes, with increased production of proteins such as COL1<3, vimentin, and decorin. Matrix metalloproteinases (MMP2, MMP8) are involved in the remodeling process, regulated by factors like HSP60. (6.) *Implant Encapsulation*: The final outcome is the encapsulation of the implant by fibrotic tissue, forming a dense fibrous capsule around the implant due to the accumulation and remodeling of ECM components.

2.3. Immediate and Chronic Inflammatory Triggers Following SMI Insertion

Immediate Post-Implantation Response

Upon the insertion of silicone mammary implants (SMIs), the body mounts an acute inflammatory response (Figure 2a) [2,45–47,50,103,104]. This is initiated by factors such as tissue damage, contamination by the skin microbiome, and the introduction of damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs) [54,55,105]. The immune system rapidly activates, recruiting immune cells like neutrophils and macrophages to clear the damaged tissue and manage the initial microbial contamination [50,55,57,105]. Additionally, microparticulate silicone may shed from the implant, migrating into surrounding tissues and exacerbating the inflammatory response. Microbial attachment to the implant surface, along with the adsorption of wound proteins, triggers further immune activation [50,105]. Inflammatory mediators such as monocyte chemoattractant protein-1 (MCP-1), collagen types I and III (COL1/3), and cellular adhesion markers like CD44 accumulate at the wound site, amplifying the acute response and setting the stage for potential fibrosis [46,50].



*Inflammatory Triggers and Early-Stage Fibrosis:* Months after implantation, persistent inflammation is driven by biofilm formation on the implant surface and the adhesion of proinflammatory and profibrotic factors. Microbial infiltration into fibrotic tissue and extensive ECM remodeling, involving vimentin, decorin, and fibronectin, result in the development of a dense fibrotic capsule.

#### Early-Stage Fibrosis (Months Post-Implantation)

As the healing process continues (Figure 2b), a persistent inflammatory state emerges [2,45]. Biofilms can develop on the implant surface, contributing to chronic inflammation due to the ongoing presence of microbial species and their adhesion to the implant [50,105]. This chronic inflammation drives the activation of pro-inflammatory and pro-fibrotic pathways, with these factors becoming incorporated into the developing fibrotic tissue around the implant [46,47]. Over time, the extracellular matrix (ECM) undergoes significant remodeling, marked by the deposition of proteins such as vimentin, decorin, and fibronectin [2,45]. These changes contribute to the formation of a dense fibrotic capsule that surrounds the implant, which is further infiltrated by microbial species, perpetuating the chronic inflammatory state [50]. Ultimately, this sustained inflammation and ECM remodeling lead to the development of capsular fibrosis and contracture around the implant [48,56,58–60,106].

#### 2.4. Influence of Surface Characteristics on Inflammation and Fibrotic Pathways

##### Surface Texture and Inflammation

The surface characteristics of silicone implants, such as texture and roughness, significantly influence the inflammatory and fibrotic responses. Textured surfaces tend to provoke a more robust inflammatory response compared to smooth surfaces. Studies have shown that rougher surfaces increase immune cell activation and cytokine secretion, contributing to heightened fibrosis and contracture [47,50,103,104,107].

Surface texture affects fibroblast behavior, including their attachment, proliferation, and differentiation [104]. Textured surfaces often lead to more pronounced fibroblast activation and increased collagen deposition, while smoother surfaces can result in less severe fibrotic responses [47,104]. This variation in fibrosis is linked to differences in cytokine profiles and immune cell interactions, with rougher surfaces promoting a more aggressive inflammatory environment [47].

##### Surface Characteristics and Cellular Responses

The impact of implant surface characteristics on cellular responses is mediated through various molecular signaling pathways. For instance, rougher surfaces may enhance the activation of NF- $\kappa$ B and TGF- $\beta$  pathways, leading to increased fibroblast activity and ECM deposition [47]. Surface roughness also influences macrophage polarization, with smoother surfaces promoting an anti-inflammatory M2 macrophage phenotype and rougher surfaces favoring a pro-inflammatory M1 phenotype [47,108,109].

### 3. Microbial Adhesion, Colonization, and Biofilm Formation on SMI

Despite rigorous adherence to sterilization and disinfection protocols [110–113], SMIs can become sites for microbial adhesion, colonization, and biofilm formation. This occurs despite the inert nature of silicone, which itself lacks antimicrobial properties [114]. The body's immune response to these implants plays a crucial role in managing microbial threats, but it also inadvertently contributes to a conducive environment for bacterial colonization, particularly when biofilms are formed on the implant surface [53–55,59,60,115,116].

#### 3.1. Microbial Transmission and Surface Adhesion

During surgical implantation, SMIs may become contaminated through various pathways, including skin microbiota, operating room environments, or surgical instruments. Staphylococcal species, particularly *Staphylococcus epidermidis*, are commonly implicated due to their ubiquitous presence on human skin and the bacterial ability to adhere to the implant surface [50,58,59]. Once


these microbes come into contact with the SMI surface, especially during the acute wound phase (24–120 hours post-operation), they begin the process of adhesion, which is influenced by the surface characteristics of the implant [50].

Surface topography is a critical determinant of microbial adhesion. Rougher surfaces, characterized by higher surface roughness (average roughness  $R_a$  60  $\mu\text{m}$ ), provide more surface area and microenvironments conducive to bacterial adherence [50,117]. This is particularly evident in studies where rougher SMI surfaces attracted more bacteria, including *S. epidermidis*, and facilitated thicker biofilm growth compared to smoother surfaces [50,106,118–122]. The initial phase of microbial adhesion involves reversible attachment, where bacteria adhere to the implant surface through weak van der Waals forces and hydrophobic interactions [123,124]. If conditions are favorable, this progresses to irreversible attachment, where bacteria anchor themselves more securely, often using surface appendages like pili or fimbriae [54,117].

### 3.2. Colonization and Biofilm Formation

Following successful adhesion, the bacteria begin to proliferate and secrete extracellular polymeric substances (EPS), forming a biofilm [54,117]. Biofilms are complex, structured communities of bacteria encased in a self-produced matrix of EPS, including polysaccharides, proteins, and DNA [54,55,125,126]. This matrix helps bacteria adhere more securely to the implant surface and provides protection from the host immune system and antibiotic treatments [54,125–128]. Biofilm formation is a key factor in the persistence of bacterial infections associated with SMIs, as bacteria within a biofilm can be up to 1,000 times more resistant to antibiotics than their planktonic (free-floating) counterparts [54,125].

Figure 3 illustrates the sequence of events from initial microbial adhesion to biofilm development, ultimately leading to capsular contracture. The transfer of skin microbiota during implant placement, early bacterial colonization, biofilm formation, and the resulting fibrous capsule formation are critical steps in the pathogenesis of implant-associated infections and complications.



**Figure 3.** Bacterial contamination and biofilm development contribute to capsular contracture. Microbial colonization during implant placement begins with the transfer of the skin microbiome to the implant surface through surgical tools and incision, embedding the implant into the lower tissue layers. *Microbial Proliferation in the Acute Wound:* The patient's skin microbiome is transferred to the implant surface during surgery, via the scalpel, incision, and implant placement. *Reversible Phase:* In this early stage, planktonic bacteria adhere to the implant surface and the adhesive proteome through electrostatic and hydrophobic forces. At this point, the bacterial adhesion is reversible, and appropriate interventions can still prevent colonization. *Irreversible Phase:* As time progresses, bacteria establish a firm attachment to the surface, proliferating and forming a biofilm. The biofilm matrix shields the bacteria from the host's immune system and antimicrobial treatments, promoting a persistent infection. *Capsule Formation and Contracture:* The persistent presence of biofilms triggers ongoing antimicrobial inflammatory reaction, contributing to the development of a fibrous capsule around the implant. This process can result in capsular contracture, where the capsule thickens and tightens, causing complications.


The biofilm development on SMIs is particularly concerning because it can lead to chronic infections that are difficult to detect and treat [53,55–58,60,116,129]. For example, subclinical infections associated with *S. epidermidis* are often asymptomatic but can result in significant complications such as capsular contracture[58,59,130,131]. The chronic nature of these infections is partly due to the immune system's inability to effectively clear biofilms, as the protective EPS matrix inhibits the penetration of immune cells and antimicrobial peptides (AMPs) [50,59].

#### 4. Reducing Capsular Contracture: Antimicrobial Strategies in Breast Implant Surgery



Sterilization and disinfection are crucial components of infection control in healthcare settings, forming the bedrock of patient and healthcare personnel safety [110]. In hospital environments, a multitude of surgical and invasive procedures are performed daily, which inherently introduces the risk of pathogen transmission. The improper sterilization or disinfection of medical instruments can result in severe infection risks, including the transmission of hepatitis B and environmental pathogens [132–136]. To mitigate these risks, healthcare facilities must employ effective decontamination methods for medical devices. Healthcare providers are pivotal in implementing these procedures to reduce and eliminate potential infections [112]. Establishing specific sterilization and disinfection guidelines based on the intended use of medical devices and associated infection risks is mandatory [110]. Given the rise of newly emerging and multidrug-resistant pathogens in healthcare centers, medical professionals need to possess a thorough understanding of these techniques to prevent the spread of infections. The International Organization of Standardization has set standardized definitions and criteria for sterilization, disinfection, and cleaning, with initial guidelines established in 2004 and subsequently updated in 2010 [111,113].

As shown in Figure 2, strategies for reducing capsular contracture in breast implant surgery emphasize the importance of infection control, including sterilization and the use of antimicrobial agents like chlorhexidine gluconate to minimize bacterial contamination. These approaches, combined with surgical techniques like the no-touch method and postoperative care protocols, play a critical role in preventing biofilm formation and ensuring better surgical outcomes.



**Figure 3.** Strategies for Reducing Capsular Contracture in Breast Implant Surgery. *Infection Control and Sterilization:* Proper sterilization and disinfection of medical instruments are emphasized to prevent pathogen transmission in healthcare settings [109,131–135]. Guidelines tailored to the specific use of medical devices and associated infection risks are critical for avoiding severe infections [109]. *Antimicrobial Approaches:* The effectiveness of preoperative antiseptics, including chlorhexidine gluconate and povidone-iodine, is compared, with a focus on their role in reducing biofilm-related capsular contracture [115,139]. The use of irrigation solutions such as Triple Antibiotic Solution (TAS), polyhexanide, and hypochlorous acid is also explored for biofilm eradication [54,59,60,143–146]. *Surgical Techniques:* Preoperative preparation, including antisepsis methods and hair removal techniques, is combined with intraoperative strategies like the no-touch technique and antimicrobial pocket irrigation to reduce bacterial exposure [161,162,165–168]. The use of sterile devices like Keller funnels and the selection of specific incision types, such as inframammary incisions, are recommended to minimize contamination risks. *Postoperative Care:* Proper wound management, including keeping the surgical

site clean and monitoring for infections, is crucial for preventing complications and ensuring optimal surgical outcomes [137,147].

#### 4.1. Antimicrobial Approaches to Mitigate Postoperative Infections and Biofilm Formation

In the context of aesthetic breast surgery, there has been a noted increase in the rate of postoperative surgical site infections (SSIs). The most commonly identified bacteria in these infections include *Staphylococcus epidermidis*, *Staphylococcus aureus*, *Escherichia coli*, *Pseudomonas aeruginosa*, *Propionibacterium acnes*, and *Corynebacterium* species [59,65,137–139]. Preoperative skin antiseptics play a critical role in reducing these postoperative complications. While povidone-iodine and other antimicrobial irrigations have been effective in reducing these complications [140], chlorhexidine gluconate has demonstrated superior efficacy in minimizing biofilm-related capsular contracture compared to povidone-iodine [116].

The relationship between bacterial contamination and implant-related complications was first elucidated by Burkhardt et al. in 1986, highlighting the significant impact of local antimicrobial agents in reducing the incidence of capsular contracture in retromammary implants [141]. Betadine pocket irrigation was once the standard practice for preventing such complications [142]; however, in 2000, the FDA contraindicated its use, prompting the adoption of alternative solutions such as triple antibiotic solution (TAS) [143]. TAS has since been associated with a substantially lower rate of capsular contracture in patients undergoing breast augmentation [57,144–147]. Although TAS is widely favored, some studies suggest that betadine-containing irrigations may be more effective in certain contexts [146,148].

The timing and duration of irrigation solutions have also been revisited, with evidence suggesting that prolonged exposure times may enhance their efficacy [149–152]. Surveys conducted among members of the American Society of Plastic Surgeons (ASPS) have highlighted the use of 0.1% polyhexanide as a preferred antimicrobial agent during breast augmentation pocket irrigation. This trend underscores its recognition within the plastic surgery community for its effectiveness in reducing bacterial contamination associated with breast prostheses. Nevertheless, there remains significant variability in the antimicrobial techniques and agents preferred by ASPS members, emphasizing the need for standardized guidelines in breast pocket irrigation and implant soaking.

Recent studies have further examined the anti-biofilm efficacy of various irrigation solutions, comparing hypochlorous acid (HOCl), polyhexanide (Lavisorb®), and octenidine-dihydrochloride/phenoxyethanol using an innovative in-vitro human plasma biofilm model [62]. Their findings revealed that hypochlorous solutions were less effective in eradicating biofilms compared to polyhexanide and octenidine-dihydrochloride/phenoxyethanol, suggesting that HOCl may not be suitable for standalone biofilm eradication [62].

Despite these advances in understanding and technique, staphylococci remain the most common microorganisms in the axillary flora, and antibiotics targeting these bacteria have not significantly impacted the incidence of SSIs [153]. Furthermore, preoperative antibiotic prophylaxis has not markedly reduced SSIs in breast cancer surgery [154,155]. Patient compliance is also critical, as noncompliance with medication regimens can double the risk of infection following breast surgery [156].

The routine application of antimicrobial pocket irrigation, the use of implant soaking agents, and various preventative strategies have been shown to collectively reduce the rates of capsular contracture [157]. However, despite the well-documented association between bacterial contamination and surgical complications, there remains a conspicuous lack of universally accepted, evidence-based guidelines for antimicrobial breast pocket irrigation and perioperative antibiotic administration. Furthermore, the literature provides conflicting evidence regarding the effectiveness of various pocket irrigation solutions, such as HOCl [158], and there is ongoing debate about the role of systemic antibiotics in preventing surgical site infections (SSI), with some studies suggesting a limited impact.

In conclusion, while significant progress has been made in understanding and addressing SSIs and capsular contracture in breast surgery, there remains a critical need for consensus on

antimicrobial practices. The establishment of evidence-based guidelines for antimicrobial irrigation in implant-based breast surgery is essential to optimize patient outcomes and reduce the incidence of complications related to bacterial contamination.

#### 4.2. Surgical Techniques for Minimizing Bacterial Contamination

During SMI implantation, minimizing bacterial contamination is crucial for reducing complications such as biofilm-associated fibrotic capsule formation [151,159–161]. Effective preoperative preparation plays a vital role in this process. Using electric clippers for hair removal instead of razors minimizes microabrasions and the risk of introducing bacteria into the surgical field [162].

During the surgical procedure, employing a no-touch technique is essential for minimizing the risk of contamination [163]. Devices like Keller funnels facilitate this approach by ensuring that implants are handled in a sterile manner, reducing the chance of bacterial exposure [163].

The technique of implant insertion also plays a significant role in controlling contamination [164]. Using sterile funnels or sleeves during the insertion process limits the implant's contact with non-sterile surfaces, further reducing bacterial exposure [163,165]. Additionally, the choice of surgical incision is important; the inframammary incision is favored over the periareolar approach due to its lower infection rates and better control over implant exposure to contaminants [164–167].

Postoperative care is equally critical in minimizing contamination risks. Proper wound care, including keeping the surgical site clean and monitoring for signs of infection, is essential to prevent complications [138,148].

In summary, the choice of surgical incision and careful postoperative care further contribute to minimizing contamination risks and ensuring optimal outcomes.

### 5. Advances in Implant-Shell-Material and Non-Pharmacological Strategies to Prevent Biofilm-Associated Fibrosis

Fibrotic capsule formation around implanted biomaterials, including breast implants, is a significant clinical issue associated with biofilm formation and microbial colonization. This chapter reviews non-pharmacological strategies that target microbial inhibition and biofilm prevention to mitigate fibrotic responses from a molecular and immunological standpoint.

#### 5.1. Physical Modifications with Antimicrobial Properties

##### Polyurethane Foam Coatings

Early efforts to modify implant surfaces involved the application of polyurethane foam coatings, which were designed to disrupt the formation of fibrotic tissue by altering the implant's surface characteristics [168–170]. Although initial studies indicated a reduction in fibrotic capsule formation, the widespread use of these coatings was curtailed due to concerns over the release of degradation products such as 2,4-toluene diamine, which raised potential toxicity issues [171]. Despite these concerns, newer iterations of polyurethane-coated implants are being investigated for their ability to control microbial adhesion and biofilm formation [169,170,172].

##### Influence of Surface Topography on Biofilm Dynamics

Surface roughness of SMIs plays a significant role in biofilm formation [106,119]. Implants with rougher surfaces (Ra 60  $\mu\text{m}$ ) have been shown to not only attract more bacteria but also support the development of thicker and more mature biofilms compared to smoother implants (Ra 4  $\mu\text{m}$ ) [50]. The increased surface area and micro-topographical features of rough implants provide niches that protect bacteria from shear forces and immune surveillance, allowing them to establish robust biofilms [173].

*In vitro* studies have further demonstrated that SMI surface texture directly influences bacterial behavior. Both *Staphylococcus aureus* and *S. epidermidis*, common culprits in implant-related infections, show increased adhesion and biofilm formation on rougher SMI surfaces [50,173]. This is

corroborated by electron microscopy, which reveals that biofilms on rough surfaces are more complex and structured than those on smoother surfaces [50,54,55,57,125].

The implications of this are significant for clinical outcomes. Rougher SMIs are more likely to harbor biofilms, which can lead to persistent infections, chronic inflammation, and increased rates of capsular contracture [48,59,106,174]. Moreover, the association between textured implants and breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is thought to be related to the enhanced likelihood of biofilm formation on these surfaces, which may trigger chronic immune responses and, in some cases, contribute to tumorigenesis [48,174].

## 5.2. Biological Matrices with Antimicrobial Properties

### Antibiotic-Impregnated Meshes

Synthetic and biological matrices impregnated with antibiotics represent a proactive approach to managing microbial contamination [175]. Antibiotic-impregnated meshes, containing agents like minocycline and rifampicin, have been shown to significantly reduce bacterial colonization and biofilm formation around implants [176]. This strategy mitigates the inflammatory and fibrotic responses associated with microbial biofilms by providing sustained antimicrobial activity at the implant site [5,177]. The effectiveness of these meshes highlights the critical role of localized antibiotic delivery in controlling fibrotic reactions.

### Spider Silk-Based Meshes

Recent advancements include the development of spider silk-based meshes, which leverage the unique properties of spider silk proteins to enhance biocompatibility and reduce biofilm formation [178–182]. These meshes act as barriers to protein and bacterial adhesion, thereby decreasing the risk of fibrotic capsule formation [178,180,182–184]. Studies have demonstrated that spider silk-based meshes can inhibit fibroblast proliferation and collagen deposition, which are key processes in fibrotic tissue formation [184]. This approach underscores the potential of biomimetic materials in managing fibrotic responses.

### Zwitterionic Polymers

Zwitterionic polymers, characterized by their dual cationic and anionic properties, exhibit superior hydrophilicity and resistance to protein adsorption [185]. These properties make zwitterionic polymers effective in preventing microbial adhesion and biofilm formation [186]. Research has shown that zwitterionic hydrogels can prevent the formation of fibrotic capsules by reducing the FBR in animal models [185,187–190]. The ability of these polymers to resist protein fouling and microbial colonization suggests a promising avenue for mitigating fibrotic responses [189].

## 6. Pharmacological Strategies to Prevent Biofilm-Associated Fibrosis in Implants

Biofilm-associated fibrosis around implants is a significant clinical challenge, primarily due to microbial infections and the subsequent fibrotic response. This chapter reviews pharmacological strategies with antimicrobial properties aimed at mitigating biofilm-associated fibrosis around implants, focusing on mechanisms of action, drug classes, and specific agents demonstrating efficacy.

### 6.1. Antibacterial Drugs

Antibacterial drugs play a crucial role in preventing biofilm formation and associated fibrosis. These drugs can be administered in various forms, including systemic, topical, or incorporated into the implant material itself.

#### Systemic Antibacterials

Systemic antibiotics such as cefazolin and gentamicin are commonly used as prophylactic measures before and during surgery. While cefazolin, a first-generation cephalosporin, is recognized for its effectiveness in reducing infections associated with breast implants [191,192], gentamicin, an

aminoglycoside, also demonstrates broad-spectrum activity against both gram-positive and gram-negative bacteria, including those commonly involved in implant infections [191,192]. However, the overall impact of these antibiotics on surgical site infection (SSI) rates continues to be a subject of debate in the literature.

### Topical Antibacterials

Topical antibiotics, including bacitracin and chlorhexidine gluconate, are applied directly to the implant or the surgical site. Bacitracin, a peptide antibiotic, is effective against gram-positive bacteria and is used in irrigation solutions to reduce bacterial load [191,193–195]. Chlorhexidine gluconate, an antiseptic with broad-spectrum antimicrobial activity, has shown efficacy in reducing microbial contamination and biofilm formation on implant surfaces [196].

### Drug Incorporation into Implants

Incorporating antibiotics into the implant material itself can provide sustained antimicrobial effects. Rifampin, a macrocyclic antibiotic, has been incorporated into implant surfaces, showing effectiveness in reducing bacterial colonization and subsequent fibrosis [197]. This approach allows for localized drug delivery, potentially reducing the need for systemic antibiotics and minimizing adverse effects.

## 6.2. Antifibrotic and Anti-Inflammatory Drugs

Fibrosis, a major consequence of chronic inflammation and infection, can be targeted with antifibrotic and anti-inflammatory drugs.

### Pirfenidone

Pirfenidone is an antifibrotic drug with established efficacy in treating idiopathic pulmonary fibrosis. It works by reducing the production of inflammatory mediators and fibroblast proliferation. In preclinical models, pirfenidone administration reduced capsule thickness and fibroblast proliferation around implants [198–201]. This drug may prove beneficial in mitigating fibrotic responses associated with biofilm infections.

### Halofuginone

Halofuginone, originally developed for veterinary use, inhibits collagen type I synthesis and the differentiation of T helper 17 cells. When grafted onto the surface of silicone implants, halofuginone significantly decreased capsule thickness and FBR in animal models [202–205]. This agent's antifibrotic properties make it a promising candidate for controlling fibrosis related to biofilm infections [206].

### Dexamethasone

Dexamethasone, a potent glucocorticoid, reduces inflammation and collagen production by modulating cytokine activity [207]. Its application in implant surgery has been shown to decrease fibrous tissue formation [193,207,208]. The intravenous administration of dexamethasone during the perioperative period may help regulate inflammation and fibrosis surrounding implants, potentially enhancing outcomes for patients susceptible to biofilm-associated fibrosis [193].

## 6.3. Integration of Antimicrobial Strategies

Effective management of biofilm-associated fibrosis often requires a combination of antimicrobial and antifibrotic approaches. For example, preoperative prophylactic antibiotics combined with local antiseptic irrigation can significantly reduce the risk of infection and biofilm formation [206]. Furthermore, while there is potential in incorporating antifibrotic agents into the implant material or using them adjunctively with antimicrobial strategies to enhance overall efficacy in preventing fibrosis, it is important to note that these strategies have primarily been demonstrated



in preclinical and animal studies. There is currently insufficient evidence to support their routine application in clinical practice. [206].

To address biofilm-associated fibrosis around SMI, significant progress has been made through both, material-based and pharmacological strategies. Non-pharmacological approaches, including physical modifications with antimicrobial properties (such as polyurethane coatings and surface topography adjustments) and innovative biological matrices (like antibiotic-impregnated meshes and spider silk-based materials), focus on preventing microbial adhesion and biofilm formation. Concurrently, pharmacological interventions involving systemic and topical antibacterials, as well as antifibrotic agents, provide targeted solutions to manage both infection and fibrosis. The integration of these strategies, as detailed in Table 2, underscores the multifaceted approach needed to effectively mitigate fibrotic responses and improve clinical outcomes related to implant-associated complications.

**Table 2.** Non-pharmacological and pharmacological strategies to prevent biofilm-associated fibrosis in implants.

Category	Strategy	Mechanism	Key Points
<b>Physical Modifications with Antimicrobial Properties</b>	<b>Polyurethane Foam Coatings</b>	Surface modification to disrupt fibrotic tissue formation	Initial reduction in fibrotic capsule formation, concerns over toxicity from degradation products [169–172].
	<b>Surface Topography</b>	Rough surfaces increase biofilm formation	Rougher surfaces (Ra 60 µm) enhance bacterial adhesion and biofilm maturity, leading to infections and capsular contracture [45,47,105,175].
<b>Biological Matrices with Antimicrobial Properties</b>	<b>Antibiotic-Impregnated Meshes</b>	Localized antibiotic delivery to reduce biofilm formation	Effective in reducing bacterial colonization and biofilm formation with sustained antimicrobial activity [176–179].
	<b>Spider Silk-Based Meshes</b>	Inhibits bacterial adhesion and fibrotic tissue formation	Biocompatible, reduces fibroblast proliferation, and collagen deposition [180–186].
	<b>Zwitterionic Polymers</b>	Superior hydrophilicity, preventing protein adsorption and microbial adhesion	Resistant to microbial colonization, preventing foreign body response and fibrotic capsules [187–191].
<b>Pharmacological Strategies</b>	<b>Systemic Antibacterials (Cefazolin, Gentamicin)</b>	Prophylactic antibiotics to prevent infections before and during surgery	Effective against gram-positive and gram-negative bacteria in breast implant surgeries [192,193].

	<b>Topical Antibacterials (Bacitracin, Chlorhexidine)</b>	Direct application to reduce bacterial load and biofilm formation	Applied during surgery to prevent contamination and infection [192,194–196].
	<b>Drug Incorporation into Implants (Rifampin)</b>	Localized, sustained antimicrobial effect from drug-coated implant surfaces	Reduces bacterial colonization and biofilm formation directly at the implant site [197].
<b>Antifibrotic and Anti-inflammatory Drugs</b>	<b>Pirfenidone</b>	Reduces inflammation and fibroblast activity	Shown to reduce capsule thickness in preclinical models, potential use in biofilm-associated fibrosis [198–201].
	<b>Halofuginone</b>	Inhibits collagen synthesis and T helper 17 cell differentiation	Reduces fibrosis and capsule formation around implants, promising antifibrotic properties [202–205].
	<b>Dexamethasone</b>	Reduces inflammation and collagen production by modulating cytokine activity	Decreases fibrous tissue formation and inflammation, improving implant surgery outcomes [194,207,208].
<b>Integration of Antimicrobial and Antifibrotic Strategies</b>	<b>Combined Approaches</b>	Use of both antimicrobial and antifibrotic strategies to prevent biofilm formation and fibrosis	Combining antibiotics with local antiseptic irrigation and antifibrotic agents enhances efficacy in preventing biofilm-associated fibrosis.

7. Clinical Implications and Future Directions

The clinical implications of microbial adhesion, colonization, and biofilm formation on SMIs are extensive, influencing both patient outcomes and the effectiveness of treatment strategies. Understanding these processes from a molecular and immunological perspective is crucial for developing improved preventive and therapeutic measures.

Biofilm formation on SMIs is a significant concern due to its impact on implant longevity and patient health. Biofilms, which consist of microorganisms embedded in a self-produced extracellular matrix, offer protection from both host immune responses and antimicrobial treatments [54,125]. This persistent biofilm can lead to chronic inflammation and fibrosis, complicating implant-related conditions. Persistent biofilms exacerbate inflammatory responses, as the biofilm matrix hinders immune cell infiltration and the effectiveness of antimicrobial peptides [54,55,125]. This chronic inflammation often results in a thick fibrous capsule around the implant, potentially leading to complications such as chronic pain, impaired function, and implant failure [53,55,58].

Current strategies to manage these issues include preoperative antimicrobial prophylaxis, antimicrobial coatings, and advanced materials designed to reduce microbial adhesion and biofilm

formation. However, the effectiveness of antimicrobial strategies remains limited due to the rise of antimicrobial resistance and variability in clinical practices [57,59,116]. The challenge of biofilm-associated infections underscores the need for more innovative and effective approaches to prevent and manage these complications.

Recent advances in material science and pharmacology offer promising solutions. Antibiotic-impregnated meshes and spider silk-based meshes represent significant progress in preventing microbial adhesion and biofilm formation [175,178]. These materials provide sustained antimicrobial activity or reduce bacterial adhesion through physical and chemical modifications. Additionally, zwitterionic polymers, known for their resistance to protein adsorption and microbial colonization, show potential in mitigating fibrotic responses [185,187]. The integration of antifibrotic and anti-inflammatory agents, such as pirfenidone, halofuginone, and dexamethasone, either incorporated into implant materials or used as adjunctive therapies, further enhances the management of biofilm-associated complications [198,202,207]. These agents can modulate the inflammatory response and reduce fibrosis, offering a targeted approach to managing complications.

Looking forward, several key areas warrant further exploration. Developing targeted antimicrobial strategies that effectively penetrate and disrupt biofilms is crucial. Novel drug delivery systems, such as nanoparticles or localized drug reservoirs, could enhance the efficacy of antimicrobial treatments [197]. Additionally, exploring biomimetic and smart materials that can dynamically respond to microbial threats represents an exciting frontier. These materials could release antimicrobial agents in response to biofilm formation or alter their properties to prevent microbial adhesion [178,185].

Personalized medicine approaches also hold significant promise. Tailoring antimicrobial and antifibrotic treatments based on individual patient factors, such as microbial flora, immune responses, and genetic predispositions, could greatly improve clinical outcomes [198,202]. Moreover, establishing standardized clinical guidelines for antimicrobial prophylaxis, implant coatings, and antifibrotic treatments is essential. Such guidelines would help ensure consistent and effective management of biofilm-associated complications across clinical settings. Ongoing research and clinical trials will be instrumental in developing these guidelines and optimizing patient care [57,59,116].

In summary (Table 3), while advances in understanding microbial contamination and biofilm formation on SMIs have led to improved management strategies, there remains a need for continued innovation and research. By focusing on targeted antimicrobial strategies, exploring novel materials, and standardizing clinical practices, we can enhance patient outcomes and address the challenges associated with biofilm formation and fibrosis.

**Table 3.** Challenges, current strategies, and future directions for improving the clinical management of biofilm-associated complications in SMI-based breast surgery.

Clinical Aspect	Challenges	Current Strategies	Future Directions
Biofilm Formation on SMIs	Persistent biofilms protect bacteria from immune responses and antimicrobials, leading to chronic inflammation and fibrosis.	Antimicrobial prophylaxis, antimicrobial coatings, and advanced material surfaces designed to reduce biofilm formation.	Develop targeted antimicrobial strategies that penetrate biofilms. Biomimetic materials that release antimicrobials in response to biofilm formation.
Chronic Inflammation and Fibrosis	Biofilm matrix limits immune cell infiltration and antimicrobial effectiveness, leading to thick fibrous capsules.	Anti-inflammatory and antifibrotic agents (pirfenidone, halofuginone, dexamethasone) to reduce fibrosis.	Incorporate anti-inflammatory and antifibrotic agents into implant materials. Personalized treatment approaches based on

			patient immune responses.
<b>Antimicrobial Resistance</b>	Resistance to traditional antimicrobial treatments is rising, making it difficult to manage biofilm infections.	Preoperative prophylaxis with systemic antibiotics; antimicrobial materials such as antibiotic-impregnated meshes.	Novel drug delivery systems (e.g., nanoparticles or localized reservoirs) that enhance antimicrobial efficacy and overcome resistance.
<b>Advanced Materials</b>	Existing materials may not fully prevent microbial adhesion or fibrosis.	Antibiotic-impregnated and spider silk-based meshes, zwitterionic polymers.	Development of smart materials that dynamically respond to microbial threats, change surface properties, or release antimicrobials.
<b>Clinical Guidelines and Practice</b>	Variability in practices and lack of standardized guidelines lead to inconsistent management of biofilm complications.	General antimicrobial prophylaxis and surface modifications for reducing biofilm risk.	Standardized clinical guidelines for antimicrobial prophylaxis, coatings, and antifibrotic treatments across clinical settings.
<b>Personalized Medicine</b>	Generalized treatments may not consider individual patient factors, leading to suboptimal outcomes.	Uniform antibiotic and antifibrotic regimens based on general risk profiles.	Personalized treatments tailored to patient-specific factors (microbial flora, immune responses, genetic predisposition).

8. Conclusions

The exploration of microbial adhesion, colonization, and biofilm formation on SMIs highlights a critical area of concern in both the molecular and clinical realms. The persistent challenge of biofilm-associated infections underscores the complexity of managing implant-related complications and the need for continued innovation in both material science and therapeutic strategies.

Biofilm formation on SMIs represents a multifaceted issue, with significant implications for patient health and implant longevity. The inherent protective properties of biofilms, which shield bacteria from both immune responses and antimicrobial treatments, contribute to the chronic nature of infections and the difficulty of eradicating these microbial communities. The extracellular polymeric substances (EPS) that form part of the biofilm matrix play a crucial role in this persistence, effectively hindering the penetration of immune cells and antimicrobial agents. This results in prolonged inflammation and fibrosis, complicating implant-related conditions and impacting patient outcomes.

Recent advancements in material science, such as the development of antimicrobial coatings, antibiotic-impregnated meshes, and spider silk-based materials, offer promising solutions to mitigate biofilm formation and reduce microbial colonization. These innovations aim to enhance the effectiveness of SMIs by either preventing bacterial adhesion or providing sustained antimicrobial activity. Zwitterionic polymers, with their resistance to protein fouling, represent another promising avenue for reducing microbial colonization and associated fibrosis. Incorporating antifibrotic and anti-inflammatory agents into implant materials or using them as adjunctive therapies further supports the management of biofilm-associated complications, providing targeted approaches to control inflammation and fibrosis.

Despite these advancements, several challenges remain. The rise of antimicrobial resistance and variability in clinical practices underscore the need for more effective and standardized approaches to antimicrobial prophylaxis and implant management. The development of targeted drug delivery systems and personalized medicine strategies could significantly improve the efficacy of treatments by tailoring interventions to individual patient factors and specific microbial threats. Additionally, establishing evidence-based guidelines for antimicrobial prophylaxis, implant coatings, and antifibrotic treatments is essential for ensuring consistent and effective management across clinical settings.

Future research should focus on several key areas: enhancing our understanding of biofilm dynamics and microbial interactions with implant surfaces, developing innovative materials that dynamically respond to microbial threats, and optimizing personalized treatment strategies. Continued investigation into novel materials and therapeutic approaches will be instrumental in addressing the challenges associated with biofilm formation and fibrosis. Clinical trials and ongoing research will play a crucial role in refining these strategies and improving patient outcomes.

In conclusion, while significant progress has been made in understanding and addressing microbial contamination and biofilm formation on SMIs, there remains a critical need for continued innovation and research. By focusing on targeted antimicrobial strategies, exploring advanced materials, and establishing standardized clinical practices, we can improve the management of implant-related complications and enhance patient care. The integration of molecular insights with practical clinical approaches will be key to overcoming the challenges posed by biofilm-associated infections and ensuring the long-term success of medical implants.

**Author Contributions:** Writing—original draft preparation, I.S.; writing—review and editing, M.L. D.C.C.-H., A.A., A.I., S.S., and D.W.; data curation, I.S.; visualization, I.S.; supervision, I.S.. D.W. acquired funding. All authors have read and agreed to the published version of the manuscript.

**Funding:** Research on this project was funded by Establishment Labs, Costa Rica (ID D152500-015-015) to D.W.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Not applicable.

**Conflicts of Interest:** The authors declare no conflicts of interest

## References

1. Noskovicova, Nina, Boris Hinz, and Pardis Pakshir. 2021. Implant Fibrosis and the Underappreciated Role of Myofibroblasts in the Foreign Body Reaction. *Cells* 2021, Vol. 10, Page 1794 10. Multidisciplinary Digital Publishing Institute: 1794. <https://doi.org/10.3390/CELLS10071794>.
2. Wick, Georg, Cecilia Grundtman, Christina Mayerl, Thomas-Florian Wimpissinger, Johann Feichtinger, Bettina Zelger, Roswitha Sgonc, and Dolores Wolfram. 2013. The immunology of fibrosis. *Annual review of immunology* 31: 107–35. <https://doi.org/10.1146/annurev-immunol-032712-095937>.
3. Wynn, Thomas A., and Thirumalai R. Ramalingam. 2012. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. *Nat Med* 18: 1028–1040. <https://doi.org/10.1038/nm.2807>.
4. Safran, Tyler, Hillary Nepon, Carrie K. Chu, Sebastian Winocour, Amanda M. Murphy, Peter G. Davison, Tassos Dionisopolos, and Joshua Vorstenbosch. 2021. Healing, Inflammation, and Fibrosis: Current Concepts in Capsular Contracture: Pathophysiology, Prevention, and Management. *Seminars in Plastic Surgery* 35. Thieme Medical Publishers: 189. <https://doi.org/10.1055/S-0041-1731793>.
5. Kadirvelu, Lohita, Sowmiya Sri Sivaramalingam, Deepshikha Jothivel, Dhivya Dharshika Chithiraiselvan, Deenadayalan Karaiyagowder Govindarajan, and Kumaravel Kandaswamy. 2024. A review on antimicrobial strategies in mitigating biofilm-associated infections on medical implants. *Current research in microbial sciences* 6. Elsevier Ltd: 100231. <https://doi.org/10.1016/j.crmicr.2024.100231>.
6. Pool, J. G. 1977. Normal hemostatic mechanisms: a review. *The American journal of medical technology* 43.
7. Furie, Bruce, and Barbara C Furie. 2008. Mechanisms of thrombus formation. *Mechanisms of Disease. The New England journal of medicine* 359.
8. Locatelli, Laura, Alessandra Colciago, Sara Castiglioni, and Jeanette A. Maier. 2021. Platelets in Wound Healing: What Happens in Space? *Frontiers in Bioengineering and Biotechnology* 9. Frontiers Media S.A. <https://doi.org/10.3389/FBIOE.2021.716184>.



9. Rodrigues, Melanie, Nina Kosaric, Clark A. Bonham, and Geoffrey C. Gurtner. 2019. Wound healing: A cellular perspective. *Physiological Reviews* 99. <https://doi.org/10.1152/physrev.00067.2017>.
10. Su, Yingjun, and Ann Richmond. 2015. Chemokine Regulation of Neutrophil Infiltration of Skin Wounds. *Advances in Wound Care* 4. <https://doi.org/10.1089/wound.2014.0559>.
11. He, Lizhi, and Alexander G. Marneros. 2013. Macrophages are essential for the early wound healing response and the formation of a fibrovascular scar. *American Journal of Pathology* 182. <https://doi.org/10.1016/j.ajpath.2013.02.032>.
12. Koh, Timothy J., and Luisa Ann DiPietro. 2011. Inflammation and wound healing: the role of the macrophage. *Expert reviews in molecular medicine* 13. <https://doi.org/10.1017/S1462399411001943>.
13. Namas, Rami A., Qi Mi, Rajaie Namas, Khalid Almahmoud, Akram M. Zaaqoq, Othman Abdul-Malak, Nabil Azhar, et al. 2015. Insights into the Role of Chemokines, Damage-Associated Molecular Patterns, and Lymphocyte-Derived Mediators from Computational Models of Trauma-Induced Inflammation. *Antioxidants and Redox Signaling*. Mary Ann Liebert Inc. <https://doi.org/10.1089/ars.2015.6398>.
14. Galli, Stephen J., Niels Borregaard, and Thomas A. Wynn. 2011. Phenotypic and functional plasticity of cells of innate immunity: Macrophages, mast cells and neutrophils. *Nature Immunology*. <https://doi.org/10.1038/ni.2109>.
15. Wilkinson, Holly N., and Matthew J. Hardman. 2023. Wound healing: Cellular mechanisms and pathological outcomes. *Advances in Surgical and Medical Specialties*. Taylor and Francis: 341–370. <https://doi.org/10.1098/RSOB.200223/>.
16. Gurtner, Geoffrey C., Sabine Werner, Yann Barrandon, and Michael T. Longaker. 2008. Wound repair and regeneration. *Nature*. <https://doi.org/10.1038/nature07039>.
17. Eilken, Hanna M., and Ralf H. Adams. 2010. Dynamics of endothelial cell behavior in sprouting angiogenesis. *Current opinion in cell biology* 22. *Curr Opin Cell Biol*: 617–625. <https://doi.org/10.1016/J.CEB.2010.08.010>.
18. Tonnesen, Marcia G., Xiaodong Feng, and Richard A.F. Clark. 2000. Angiogenesis in wound healing. *The journal of investigative dermatology. Symposium proceedings* 5. *J Investig Dermatol Symp Proc*: 40–46. <https://doi.org/10.1046/J.1087-0024.2000.00014.X>.
19. Li, Jie, Yan Ping Zhang, and Robert S. Kirsner. 2003. Angiogenesis in wound repair: Angiogenic growth factors and the extracellular matrix. *Microscopy Research and Technique* 60. Wiley-Liss Inc.: 107–114. <https://doi.org/10.1002/JEMT.10249>.
20. Mascharak, Shamik, Heather E. desJardins-Park, and Michael T. Longaker. 2020. Fibroblast Heterogeneity in Wound Healing: Hurdles to Clinical Translation. *Trends in Molecular Medicine*. <https://doi.org/10.1016/j.molmed.2020.07.008>.
21. Kohan, Martin, Andres F. Muro, Eric S. White, and Neville Berkman. 2010. EDA-containing cellular fibronectin induces fibroblast differentiation through binding to alpha4beta7 integrin receptor and MAPK/Erk 1/2-dependent signaling. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 24. *FASEB J*: 4503–4512. <https://doi.org/10.1096/FJ.10-154435>.
22. Serini, Guido, Marie Luce Bochaton-Piallat, Patricia Ropraz, Antoine Geinoz, Laura Borsi, Luciano Zardi, and Giulio Gabbiani. 1998. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. *The Journal of cell biology* 142. *J Cell Biol*: 873–881. <https://doi.org/10.1083/JCB.142.3.873>.
23. Shinde, Arti V., Claudio Humeres, and Nikolaos G. Frangogiannis. 2017. The role of  $\alpha$ -smooth muscle actin in fibroblast-mediated matrix contraction and remodeling. *Biochimica et biophysica acta* 1863. NIH Public Access: 298. <https://doi.org/10.1016/J.BBADIS.2016.11.006>.
24. Darby, Ian A., Betty Laverdet, Frédéric Bonté, and Alexis Desmoulière. 2014. Fibroblasts and myofibroblasts in wound healing. *Clinical, cosmetic and investigational dermatology* 7. *Clin Cosmet Investig Dermatol*: 301–311. <https://doi.org/10.2147/CCID.S50046>.
25. Thulabandu, Venkata, Demeng Chen, and Radhika P. Atit. 2018. Dermal fibroblast in cutaneous development and healing. *Wiley Interdisciplinary Reviews: Developmental Biology* 7. John Wiley & Sons, Ltd: e307. <https://doi.org/10.1002/WDEV.307>.
26. Bainbridge, P. 2013. Wound healing and the role of fibroblasts. *Journal of Wound Care* 22. MA Healthcare Ltd: 407–412. <https://doi.org/10.12968/JOWC.2013.22.8.407>.
27. Pakshir, Pardis, Nina Noskovicova, Monika Lodyga, Dong Ok Son, Ronen Schuster, Amanda Goodwin, Henna Karvonen, and Boris Hinz. 2020. The myofibroblast at a glance. *Journal of Cell Science* 133. Company of Biologists Ltd. <https://doi.org/10.1242/JCS.227900>.
28. Hinz, B. 2016. The role of myofibroblasts in wound healing. *Current Research in Translational Medicine* 64. Elsevier Masson SAS: 171–177. <https://doi.org/10.1016/J.RETRAM.2016.09.003>.
29. Hinz, Boris, Christopher A. McCulloch, and Nuno M. Coelho. 2019. Mechanical regulation of myofibroblast phenoconversion and collagen contraction. *Experimental Cell Research* 379. Elsevier Inc.: 119–128. <https://doi.org/10.1016/J.YEXCR.2019.03.027>.

30. Klingberg, Franco, Boris Hinz, and Eric S. White. 2013. The myofibroblast matrix: implications for tissue repair and fibrosis. *The Journal of Pathology* 229. John Wiley & Sons, Ltd: 298–309. <https://doi.org/10.1002/PATH.4104>.
31. Lindley, Linsey E., Olivera Stojadinovic, Irena Pastar, and Marjana Tomic-Canic. 2016. Biology and biomarkers for wound healing. *Plastic and Reconstructive Surgery* 138. <https://doi.org/10.1097/PRS.0000000000002682>.
32. Hartman, Erik, Karl Wallblom, Mariena J.A. van der Plas, Jitka Petrlova, Jun Cai, Karim Saleh, Sven Kjellström, and Artur Schmidtchen. 2021. Bioinformatic Analysis of the Wound Peptidome Reveals Potential Biomarkers and Antimicrobial Peptides. *Frontiers in Immunology* 11. Frontiers Media S.A.: 3765. <https://doi.org/10.3389/FIMMU.2020.620707/BIBTEX>.
33. Han, George, and Roger Ceilley. 2017. Chronic Wound Healing: A Review of Current Management and Treatments. *Advances in Therapy* 34. Springer Healthcare: 599–610. <https://doi.org/10.1007/S12325-017-0478-Y>.
34. Gonzalez, Ana Cristina De Oliveira, Zilton De Araújo Andrade, Tila Fortuna Costa, and Alena Ribeiro Alves Peixoto Medrado. 2016. Wound healing - A literature review. *Anais Brasileiros de Dermatologia*. <https://doi.org/10.1590/abd1806-4841.20164741>.
35. Ng, Michael Fy. 2010. The role of mast cells in wound healing. *International Wound Journal*. <https://doi.org/10.1111/j.1742-481X.2009.00651.x>.
36. Komi, Daniel Elieh Ali, Kelly Khomtchouk, and Peter Luke Santa Maria. 2020. A Review of the Contribution of Mast Cells in Wound Healing: Involved Molecular and Cellular Mechanisms. *Clinical Reviews in Allergy and Immunology* 58. Springer: 298–312. <https://doi.org/10.1007/S12016-019-08729-W>.
37. Jiang, Dongsheng, and Yuval Rinkevich. 2020. Scars or regeneration?—dermal fibroblasts as drivers of diverse skin wound responses. *International Journal of Molecular Sciences* 21. MDPI AG. <https://doi.org/10.3390/IJMS21020617>.
38. Cohen, I. Kelman. 2007. Lessons from the history of wound healing. *Clinics in Dermatology* 25: 3–8. <https://doi.org/10.1016/J.CLINDERMATOL.2006.12.004>.
39. Li, Hui, E. Cai, Hongyan Cheng, Xue Ye, Ruiqiong Ma, Honglan Zhu, and Xiaohong Chang. 2022. FGA Controls VEGFA Secretion to Promote Angiogenesis by Activating the VEGFR2-FAK Signalling Pathway. *Frontiers in endocrinology* 13. Front Endocrinol (Lausanne). <https://doi.org/10.3389/FENDO.2022.791860>.
40. Margadant, Coert, and Arnoud Sonnenberg. 2010. Integrin-TGF- $\beta$  crosstalk in fibrosis, cancer and wound healing. *EMBO Reports*. <https://doi.org/10.1038/embor.2009.276>.
41. Jayaraman, Pushpa, Isabel Sada-Ovalle, Tomoyasu Nishimura, Ana C. Anderson, Vijay K. Kuchroo, Heinz G. Remold, and Samuel M. Behar. 2013. IL-1 $\beta$  Promotes Antimicrobial Immunity in Macrophages by Regulating TNFR Signaling and caspase-3 activation. *Journal of immunology (Baltimore, Md. : 1950)* 190. NIH Public Access: 4196. <https://doi.org/10.4049/JIMMUNOL.1202688>.
42. Veves, Aristidis. 2016. Discussion: Biology and biomarkers for wound healing. *Plastic and Reconstructive Surgery*. <https://doi.org/10.1097/PRS.0000000000002698>.
43. Perry, D., and Jd Frame. 2020. The history and development of breast implants. *Annals of The Royal College of Surgeons of England* 102. Royal College of Surgeons of England: 478. <https://doi.org/10.1308/RCSANN.2020.0003>.
44. Ghazal, Ismat D., Chimdi Eleweke, Francisca O. Aladesanwa, and Bayowa O. Onabajo. 2023. Post-mastectomy breast reconstruction: an overview of the state of the art, challenges, and prospects. *International Surgery Journal* 10. Medip Academy: 348–354. <https://doi.org/10.18203/2349-2902.ISJ20230283>.
45. Wick, Georg, Aleksandar Backovic, Evelyn Rabensteiner, Nadine Plank, Christian Schwentner, and Roswitha Sgonc. 2010. The immunology of fibrosis: innate and adaptive responses. *Trends in immunology* 31. Europe PMC Funders: 110. <https://doi.org/10.1016/J.IT.2009.12.001>.
46. Schoberleitner, Ines, Klaus Faserl, Bettina Sarg, Daniel Egle, Christine Brunner, and Dolores Wolfram. 2023. Quantitative Proteomic Characterization of Foreign Body Response towards Silicone Breast Implants Identifies Chronological Disease-Relevant Biomarker Dynamics. *Biomolecules* 13. MDPI. <https://doi.org/10.3390/BIOM13020305>.
47. Schoberleitner, Ines, Klaus Faserl, Christoph H Tripp, Elisabeth Judith Pechriggl, Stephan Sigl, Andrea Brunner, Bettina Zelger, et al. 2024. Silicone implant surface microtopography modulates inflammation and tissue repair in capsular fibrosis. *Frontiers in Immunology* 15. Frontiers: 1342895. <https://doi.org/10.3389/FIMMU.2024.1342895>.
48. Mempin, Maria, Honghua Hu, Durdana Chowdhury, Anand Deva, and Karen Vickery. 2018. The A, B and C's of silicone breast implants: Anaplastic large cell lymphoma, biofilm and capsular contracture. *Materials*. MDPI AG. <https://doi.org/10.3390/ma11122393>.
49. Zhang, Li, El Mustapha Haddouti, Kristian Welle, Christof Burger, Dieter C. Wirtz, Frank A. Schildberg, and Koroush Kabir. 2020. The Effects of Biomaterial Implant Wear Debris on Osteoblasts. *Frontiers in Cell and Developmental Biology*. <https://doi.org/10.3389/fcell.2020.00352>.

50. Schoberleitner, Ines, Leoni Baier, Michaela Lackner, Lisa-Maria Zenz, Débora C. Coraça-Huber, Wendy Ullmer, Annabelle Damerum, et al. 2024. Surface Topography, Microbial Adhesion, and Immune Responses in Silicone Mammary Implant-Associated Capsular Fibrosis. *International Journal of Molecular Sciences* 25. MDPI AG: 3163. <https://doi.org/10.3390/IJMS25063163/S1>.
51. Trojanek, Joanna B., Jacek Michałkiewicz, Renata Grzywa-Czuba, Wojciech Jańczyk, Lidia Gackowska, Izabela Kubiszewska, Anna Helmin-Basa, Aldona Wierzbička-Rucińska, Mieczysław Szalecki, and Piotr Socha. 2020. Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Peripheral Blood Leukocytes and Plasma of Children with Nonalcoholic Fatty Liver Disease. *Mediators of Inflammation* 2020. Hindawi Limited. <https://doi.org/10.1155/2020/8327945>.
52. Singh, Drishtant, Vikrant Rai, and Devendra K Agrawal. 2023. Regulation of Collagen I and Collagen III in Tissue Injury and Regeneration. *Cardiology and cardiovascular medicine* 7. NIH Public Access: 5. <https://doi.org/10.26502/FCCM.92920302>.
53. Marcinkiewicz, Janusz, Magdalena Strus, and Ewa Pasich. 2013. Antibiotic resistance: A “dark side” of biofilm-associated chronic infections. *Polskie Archiwum Medycyny Wewnętrznej*. <https://doi.org/10.20452/pamw.1780>.
54. Donlan, Rodney M. 2002. Biofilms: Microbial Life on Surfaces. *Emerging Infectious Diseases* 8. Centers for Disease Control and Prevention: 881. <https://doi.org/10.3201/EID0809.020063>.
55. Costerton, J. W., Philip S. Stewart, and E. P. Greenberg. 1999. Bacterial biofilms: A common cause of persistent infections. *Science* 284: 1318–1322. <https://doi.org/10.1126/SCIENCE.284.5418.1318>.
56. Deva, Anand K., and Lionel C. Chang. 1999. Bacterial biofilms: A cause for accelerated capsular contracture? *Aesthetic Surgery Journal* 19. Mosby Inc.: 130–133. [https://doi.org/10.1053/AQ.1999.V19.97038/2/10.1053\\_AQ.1999.V19.97038-FIG4.JPEG](https://doi.org/10.1053/AQ.1999.V19.97038/2/10.1053_AQ.1999.V19.97038-FIG4.JPEG).
57. Deva, Anand K., William P. Adams, and Karen Vickery. 2013. The role of bacterial biofilms in device-associated infection. *Plastic and Reconstructive Surgery* 132. Lippincott Williams and Wilkins: 1319–1328. <https://doi.org/10.1097/PRS.0B013E3182A3C105>.
58. del Pozo, Jose L., and Cristina Auba. 2015. Role of biofilms in breast implant associated infections and capsular contracture. *Advances in Experimental Medicine and Biology* 831. Springer New York LLC: 53–67. [https://doi.org/10.1007/978-3-319-09782-4\\_5](https://doi.org/10.1007/978-3-319-09782-4_5).
59. Ajdic, Dragana, Yasmina Zoghbi, David Gerth, Zubin J. Panthaki, and Seth Thaller. 2016. The relationship of bacterial biofilms and capsular contracture in breast implants. *Aesthetic Surgery Journal* 36. Oxford University Press: 297–309. <https://doi.org/10.1093/ASJ/SJV177>.
60. Rieger, U. M., J. Mesina, D. F. Kalbermatten, M. Haug, H. P. Frey, R. Pico, R. Frei, G. Pierer, N. J. Lüscher, and A. Trampuz. 2013. Bacterial biofilms and capsular contracture in patients with breast implants. *The British journal of surgery* 100. Br J Surg: 768–774. <https://doi.org/10.1002/BJS.9084>.
61. Ji, Litong, Tie Wang, Lining Tian, Hongjiang Song, and Meizhuo Gao. 2020. Roxatidine inhibits fibrosis by inhibiting NF-κB and MAPK signaling in macrophages sensing breast implant surface materials. *Molecular Medicine Reports* 21. Spandidos Publications: 161–172. <https://doi.org/10.3892/mmr.2019.10815>.
62. Rembe, Julian Dario, Lioba Huelsboemer, Isabell Plattfaut, Manuela Besser, and Ewa K. Stuermer. 2020. Antimicrobial Hypochlorous Wound Irrigation Solutions Demonstrate Lower Anti-biofilm Efficacy Against Bacterial Biofilm in a Complex in-vitro Human Plasma Biofilm Model (hpBIOM) Than Common Wound Antimicrobials. *Frontiers in microbiology* 11. Front Microbiol. <https://doi.org/10.3389/FMICB.2020.564513>.
63. Epps, Mathew T., Sarah Langsdon, Taylor K. Pels, Tara M. Lee, Todd Thurston, and Mark A. Brzeziński. 2019. Antimicrobial Irrigation and Technique during Breast Augmentation: Survey of Current Practice. *Plastic and Reconstructive Surgery Global Open* 7. Wolters Kluwer Health. <https://doi.org/10.1097/GOX.0000000000002310>.
64. Gofstein-Hayuth, Dina, Ehud Fliss, Yoav Barnea, Carolina Legarda, Gal Bracha, Anat Lerner, Jonathan Lellouche, Yehuda Carmeli, Nir Shani, and Ehud Arad. 2023. Comparing the efficacy of antimicrobial pocket-irrigation protocols in an in vivo breast implant infection model. *Journal of Plastic, Reconstructive and Aesthetic Surgery* 85. <https://doi.org/10.1016/j.bjps.2023.06.062>.
65. Federica, Giuzio, Fabrizio Tommaso, Catalano Alessia, Ceccarini Agostino, Bodog Florian, Giuliani Antonio, Massariello Domenico Nicola, et al. 2023. Use of Antimicrobial Irrigation and Incidence of Capsular Contracture in Breast Augmentation and Immediate Implant-Based Breast Reconstruction. *Aesthetic Plastic Surgery*. Springer: 1–6. <https://doi.org/10.1007/S00266-023-03453-5/TABLES/1>.
66. Pakshir, Pardis, and Boris Hinz. 2018. The big five in fibrosis: Macrophages, myofibroblasts, matrix, mechanics, and miscommunication. *Matrix Biology* 68–69. Elsevier B.V.: 81–93. <https://doi.org/10.1016/J.MATBIO.2018.01.019>.
67. Mack, Matthias. 2018. Inflammation and fibrosis. *Matrix Biology*. Elsevier B.V. <https://doi.org/10.1016/j.matbio.2017.11.010>.

68. Moore, Laura Beth, and Themis R. Kyriakides. 2015. Molecular characterization of macrophage-biomaterial interactions. *Advances in Experimental Medicine and Biology* 865. Springer New York LLC: 109–122. [https://doi.org/10.1007/978-3-319-18603-0\\_7](https://doi.org/10.1007/978-3-319-18603-0_7).
69. Sheikh, Zeeshan, Patricia J. Brooks, Oriyah Barzilay, Noah Fine, and Michael Glogauer. 2015. Macrophages, foreign body giant cells and their response to implantable biomaterials. *Materials* 8. MDPI AG: 5671–5701. <https://doi.org/10.3390/MA8095269>.
70. Sakar, Mahmut Selman, Jeroen Eyckmans, Roel Pieters, Daniel Eberli, Bradley J. Nelson, and Christopher S. Chen. 2016. Cellular forces and matrix assembly coordinate fibrous tissue repair. *Nature Communications* 7. Nature Publishing Group. <https://doi.org/10.1038/NCOMMS11036>.
71. Schuster, Ronen, Jason S. Rockel, Mohit Kapoor, and Boris Hinz. 2021. The inflammatory speech of fibroblasts. *Immunological Reviews* 302. John Wiley and Sons Inc: 126–146. <https://doi.org/10.1111/IMR.12971>.
72. Witherel, Claire E., Daniel Abebayehu, Thomas H. Barker, and Kara L. Spiller. 2019. Macrophage and Fibroblast Interactions in Biomaterial-Mediated Fibrosis. *Advanced Healthcare Materials* 8. Wiley-VCH Verlag. <https://doi.org/10.1002/ADHM.201801451>.
73. Hinz, B., G. Celetta, J. J. Tomasek, G. Gabbiani, and C. Chaponnier. 2001. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. *Molecular biology of the cell* 12. Mol Biol Cell: 2730–2741. <https://doi.org/10.1091/MB.12.9.2730>.
74. Moyer, Kurtis E., and H. Paul Ehrlich. 2013. Capsular contracture after breast reconstruction: collagen fiber orientation and organization. *Plast Reconstr Surg* 131: 680–685. <https://doi.org/10.1097/prs.0b013e31828189d0>.
75. Cheung, David T., Paul D. Benya, Natasha Perelman, Paul E. Dicesare, and Marcel E. Nimni. 1990. A highly specific and quantitative method for determining type III/I collagen ratios in tissues. *Matrix (Stuttgart, Germany)* 10. Matrix: 164–171. [https://doi.org/10.1016/S0934-8832\(11\)80165-4](https://doi.org/10.1016/S0934-8832(11)80165-4).
76. Akilbekova, Dana, and Kaitlin M. Bratlie. 2015. Quantitative Characterization of Collagen in the Fibrotic Capsule Surrounding Implanted Polymeric Microparticles through Second Harmonic Generation Imaging. *PLoS ONE* 10. PLOS. <https://doi.org/10.1371/JOURNAL.PONE.0130386>.
77. Wolfram, Dolores, Christian Rainer, Harald Niederegger, Hildegunde Piza, and Georg Wick. 2004. Cellular and molecular composition of fibrous capsules formed around silicone breast implants with special focus on local immune reactions \*. *Journal of Autoimmunity* 23. Academic Press: 81–91. <https://doi.org/10.1016/j.jaut.2004.03.005>.
78. Biernacka, Anna, Marcin Dobaczewski, and Nikolaos G. Frangogiannis. 2011. TGF- $\beta$  signaling in fibrosis. *Growth Factors* 29: 196–202. <https://doi.org/10.3109/08977194.2011.595714>.
79. Meng, Xiao Ming, David J. Nikolic-Paterson, and Hui Yao Lan. 2016. TGF- $\beta$ : The master regulator of fibrosis. *Nature Reviews Nephrology*. Nature Publishing Group. <https://doi.org/10.1038/nrneph.2016.48>.
80. Hu, He He, Dan Qian Chen, Yan Ni Wang, Ya Long Feng, Gang Cao, Nosratola D. Vaziri, and Ying Yong Zhao. 2018. New insights into TGF- $\beta$ /Smad signaling in tissue fibrosis. *Chemico-Biological Interactions*. Elsevier Ireland Ltd. <https://doi.org/10.1016/j.cbi.2018.07.008>.
81. Liu, Ting, Lingyun Zhang, Donghyun Joo, and Shao Cong Sun. 2017. NF- $\kappa$ B signaling in inflammation. *Signal Transduction and Targeted Therapy* 2017 2:1 2. Nature Publishing Group: 1–9. <https://doi.org/10.1038/sigtrans.2017.23>.
82. Dondossola, Eleonora, Boris M. Holzapfel, Stephanie Alexander, Stefano Filippini, Dietmar W. Hutmacher, and Peter Friedl. 2016. Examination of the foreign body response to biomaterials by nonlinear intravital microscopy. *Nature biomedical engineering* 1. Nat Biomed Eng. <https://doi.org/10.1038/S41551-016-0007>.
83. Miron, Richard J., and Dieter D. Bosshardt. 2018. Multinucleated Giant Cells: Good Guys or Bad Guys? *Tissue engineering. Part B, Reviews* 24. Tissue Eng Part B Rev: 53–65. <https://doi.org/10.1089/TEN.TEB.2017.0242>.
84. McNally, Amy K., and James M. Anderson. 2015. Phenotypic expression in human monocyte-derived interleukin-4-induced foreign body giant cells and macrophages in vitro: dependence on material surface properties. *Journal of biomedical materials research. Part A* 103. J Biomed Mater Res A: 1380–1390. <https://doi.org/10.1002/JBM.A.35280>.
85. Volk, Susan W., Yanjian Wang, Elizabeth A. Mauldin, Kenneth W. Liechty, and Sherrill L. Adams. 2011. Diminished Type III Collagen Promotes Myofibroblast Differentiation and Increases Scar Deposition in Cutaneous Wound Healing. *Cells, Tissues, Organs* 194. Karger Publishers: 25. <https://doi.org/10.1159/000322399>.
86. Desmoulière, Alexis, Christine Chaponnier, and Giulio Gabbiani. 2005. Tissue repair, contraction, and the myofibroblast. *Wound Repair and Regeneration* 13: 7–12. <https://doi.org/10.1111/J.1067-1927.2005.130102.X>.
87. De Bakker, Erik, Mathijs Rots, Marlon E. Buncamper, Frank B. Niessen, Jan Maerten Smit, Henri A.H. Winters, Müjde Özer, Henrica C.W. De Vet, and Margriet G. Mullender. 2020. The Baker Classification for Capsular Contracture in Breast Implant Surgery Is Unreliable as a Diagnostic Tool. *Plastic and reconstructive surgery* 146. Plast Reconstr Surg: 956–962. <https://doi.org/10.1097/PRS.00000000000007238>.



88. Spear, S L, and J L Baker. 1995. Classification of capsular contracture after prosthetic breast reconstruction. *Plastic and reconstructive surgery* 96: 1119–23; discussion 1124.
89. Hall-Findlay, Elizabeth J. 2020. Discussion: The baker classification for capsular contracture in breast implant surgery is unreliable as a diagnostic tool. *Plastic and Reconstructive Surgery*. Lippincott Williams and Wilkins: 963. <https://doi.org/10.1097/PRS.00000000000007312>.
90. Bachour, Yara, Stephan P. Verweij, Susan Gibbs, Johannes C.F. Ket, Marco J.P.F. Ritt, Frank B. Niessen, and Margriet G. Mullender. 2018. The aetiopathogenesis of capsular contracture: A systematic review of the literature. *Journal of Plastic, Reconstructive and Aesthetic Surgery*. Churchill Livingstone. <https://doi.org/10.1016/j.bjps.2017.12.002>.
91. Lan, Hui Yao. 2011. Diverse roles of TGF- $\beta$ /Smads in renal fibrosis and inflammation. *International Journal of Biological Sciences*. Ivyspring International Publisher. <https://doi.org/10.7150/ijbs.7.1056>.
92. Mirastschijski, Ursula, Reinhild Schnabel, Juliane Claes, Wolfgang Schneider, Magnus S. Ågren, Carol Haaksmma, and James J. Tomasek. 2010. Matrix metalloproteinase inhibition delays wound healing and blocks the latent transforming growth factor- $\beta$ 1-promoted myofibroblast formation and function. *Wound Repair and Regeneration* 18: 223–234. <https://doi.org/10.1111/J.1524-475X.2010.00574.X>.
93. Zhang, Mengjuan, and Song Zhang. 2020. T Cells in Fibrosis and Fibrotic Diseases. *Frontiers in Immunology*. Frontiers Media S.A. <https://doi.org/10.3389/fimmu.2020.01142>.
94. Iwanaga, Naoki, Jay K Kolls, John W Deming, and Endowed Chair. 2019. Updates on T helper type 17 immunity in respiratory disease. *Wiley Online Library* 156. Blackwell Publishing Ltd: 3–8. <https://doi.org/10.1111/imm.13006>.
95. Zhang, Song. 2018. The role of transforming growth factor b in T helper 17 differentiation. *Immunology* 155. John Wiley & Sons Ltd: 24–35. <https://doi.org/10.1111/imm.12938>.
96. Sakaguchi, Shimon, Norihisa Mikami, James B. Wing, Atsushi Tanaka, Kenji Ichiyama, and Naganari Ohkura. 2020. Regulatory T Cells and Human Disease. *Annual Review of Immunology* 38. Annual Reviews Inc.: 541–566. <https://doi.org/10.1146/annurev-immunol-042718-041717>.
97. Wolfram, Dolores, Evelyn Rabensteiner, Cecilia Grundtman, Günther Böck, Christina Mayerl, Walther Parson, Giovanni Almanzar, Carlo Hasenöhl, Hildegunde Piza-Katzer, and Georg Wick. 2012. T regulatory cells and TH17 cells in peri-silicone implant capsular fibrosis. *Plastic and Reconstructive Surgery*. <https://doi.org/10.1097/PRS.0b013e31823aeacf>.
98. Singh, P ;, S A Ali, E Kalyuzhny, Parul Singh, and Syed Azmal Ali. 2022. Multifunctional Role of S100 Protein Family in the Immune System: An Update. *Cells* 2022, Vol. 11, Page 2274 11. Multidisciplinary Digital Publishing Institute: 2274. <https://doi.org/10.3390/CELLS11152274>.
99. Gonzalez, Laura L., Karin Garrie, and Mark D. Turner. 2020. Role of S100 proteins in health and disease. *Biochimica et Biophysica Acta (BBA) - Molecular Cell Research* 1867. Elsevier: 118677. <https://doi.org/10.1016/J.BBAMCR.2020.118677>.
100. Sreejit, Gopalkrishna, Michelle C. Flynn, Mallikarjun Patil, Prasanna Krishnamurthy, Andrew J. Murphy, and Prabhakara R. Nagareddy. 2020. S100 family proteins in inflammation and beyond. *Advances in Clinical Chemistry* 98. Elsevier: 173–231. <https://doi.org/10.1016/BS.ACC.2020.02.006>.
101. Araki, Kota, Rie Kinoshita, Nahoko Tomonobu, Yuma Gohara, Shuta Tomida, Yuta Takahashi, Satoru Senoo, et al. 2021. The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis. *Journal of molecular medicine (Berlin, Germany)* 99. J Mol Med (Berl): 131–145. <https://doi.org/10.1007/S00109-020-02001-X>.
102. Darby, Ian A., and Tim D. Hewitson. 2007. Fibroblast Differentiation in Wound Healing and Fibrosis. *International Review of Cytology* 257: 143–179. [https://doi.org/10.1016/S0074-7696\(07\)57004-X](https://doi.org/10.1016/S0074-7696(07)57004-X).
103. Cappellano, Giuseppe, Christian Ploner, Susanne Lobenwein, Sieghart Sopfer, Paul Hoertnagl, Christina Mayerl, Nikolaus Wick, Gerhard Pierer, Georg Wick, and Dolores Wolfram. 2018. Immunophenotypic characterization of human T cells after in vitro exposure to different silicone breast implant surfaces. *PLoS ONE*. <https://doi.org/10.1371/journal.pone.0192108>.
104. Doloff, Joshua C., Omid Veisesh, Roberto de Mezerville, Marcos Sforza, Tracy Ann Perry, Jennifer Haupt, Morgan Jamiel, et al. 2021. The surface topography of silicone breast implants mediates the foreign body response in mice, rabbits and humans. *Nature Biomedical Engineering* 5. Nature Research: 1115–1130. <https://doi.org/10.1038/S41551-021-00739-4>.
105. Bizjak, Mojca, Carlo Selmi, Sonja Praprotnik, Or Bruck, Carlo Perricone, Michael Ehrenfeld, and Yehuda Shoenfeld. 2015. Silicone implants and lymphoma: The role of inflammation. *Journal of Autoimmunity*. Academic Press. <https://doi.org/10.1016/j.jaut.2015.08.009>.
106. Brauman, Daniel. 2019. Rough Textured Silicone Implants, Bacterial Biofilms, and Capsular Contracture. *Plastic and Reconstructive Surgery*. <https://doi.org/10.1097/PRS.00000000000005816>.
107. Schoberleitner, Ines, Angela Augustin, Daniel Egle, Christine Brunner, Birgit Amort, Bettina Zelger, Andrea Brunner, and Dolores Wolfram. 2023. Is It All about Surface Topography? An Intra-Individual Clinical Outcome Analysis of Two Different Implant Surfaces in Breast Reconstruction. *Journal of clinical medicine* 12. J Clin Med. <https://doi.org/10.3390/JCM12041315>.



108. Abaricia, Jefferson O., Negin Farzad, Tyler J. Heath, Jamelle Simmons, Lais Morandini, and Rene Olivares-Navarrete. 2021. Control of innate immune response by biomaterial surface topography, energy, and stiffness. *Acta Biomaterialia* 133. Acta Materialia Inc: 58–73. <https://doi.org/10.1016/j.ACTBIO.2021.04.021>.
109. Love, Ryan J., and Kim S. Jones. 2013. The recognition of biomaterials: Pattern recognition of medical polymers and their adsorbed biomolecules. *Journal of Biomedical Materials Research - Part A* 101 A: 2740–2752. <https://doi.org/10.1002/JBM.A.34577>.
110. Mohapatra, S. 2017. Sterilization and Disinfection. *Essentials of Neuroanesthesia*. Elsevier: 929. <https://doi.org/10.1016/B978-0-12-805299-0.00059-2>.
111. Belay, Ermias D., Lawrence B. Schonberger, Paul Brown, Suzette A. Priola, Bruce Chesebro, Robert G. Will, and David M. Asher. 2010. Disinfection and Sterilization of Prion-Contaminated Medical Instruments. *Infection Control & Hospital Epidemiology* 31. Cambridge University Press (CUP): 1304–1306. <https://doi.org/10.1086/657579>.
112. Rutala, William A., and David J. Weber. 2001. New disinfection and sterilization methods. *Emerging infectious diseases* 7. Emerg Infect Dis: 348–353. <https://doi.org/10.3201/EID0702.010241>.
113. Rutala, William A., and David J. Weber. 2010. Guideline for Disinfection and Sterilization of Prion-Contaminated Medical Instruments. *Infection Control & Hospital Epidemiology* 31. Cambridge University Press (CUP): 107–117. <https://doi.org/10.1086/650197>.
114. Lam, Mylan, Véronique Migonney, and Céline Falentin-Daudre. 2021. Review of silicone surface modification techniques and coatings for antibacterial/antimicrobial applications to improve breast implant surfaces. *Acta Biomaterialia*. Acta Materialia Inc. <https://doi.org/10.1016/j.actbio.2020.11.020>.
115. Dapunt, Ulrike, Birgit Prior, Jan Philippe Kretzer, Thomas Giese, and Yina Zhao. 2020. Bacterial Biofilm Components Induce an Enhanced Inflammatory Response Against Metal Wear Particles. *Therapeutics and clinical risk management* 16. Ther Clin Risk Manag: 1203–1212. <https://doi.org/10.2147/TCRM.S280042>.
116. Carvajal, Jenny, Melissa Carvajal, and Gilma Hernández. 2019. Back to Basics: Could the Preoperative Skin Antiseptic Agent Help Prevent Biofilm-Related Capsular Contracture? *Aesthetic Surgery Journal* 39. <https://doi.org/10.1093/asj/sjy216>.
117. Rezende-Pereira, Gabriel, Julia P. Albuquerque, Monica C. Souza, Barbara A. Nogueira, Marlei G. Silva, Raphael Hirata, Ana L. Mattos-Guaraldi, Rafael S. Duarte, and Felipe P.G. Neves. 2021. Biofilm Formation on Breast Implant Surfaces by Major Gram-Positive Bacterial Pathogens. *Aesthetic Surgery Journal* 41. <https://doi.org/10.1093/asj/sjaa416>.
118. Mu, Minchen, Shuhao Liu, William DeFlorio, Li Hao, Xunhao Wang, Karla Solis Salazar, Matthew Taylor, et al. 2023. Influence of Surface Roughness, Nanostructure, and Wetting on Bacterial Adhesion. *Langmuir* 39. American Chemical Society: 5426–5439. [https://doi.org/10.1021/ACS.LANGMUIR.3C00091/ASSET/IMAGES/LARGE/LA3C00091\\_0006.JPEG](https://doi.org/10.1021/ACS.LANGMUIR.3C00091/ASSET/IMAGES/LARGE/LA3C00091_0006.JPEG).
119. James, Garth A., Laura Boegli, John Hancock, Lisa Bowersock, Albert Parker, and Brian M. Kinney. 2019. Bacterial Adhesion and Biofilm Formation on Textured Breast Implant Shell Materials. *Aesthetic plastic surgery* 43. Aesthetic Plast Surg: 490–497. <https://doi.org/10.1007/S00266-018-1234-7>.
120. Josse, J., F. Laurent, and A. Diot. 2017. Staphylococcal adhesion and host cell invasion: fibronectin-binding and other mechanisms. *Front Microbiol* 8: 2433.
121. Yoda, Itaru, Hironobu Koseki, Masato Tomita, Takayuki Shida, Hidehiko Horiuchi, Hideyuki Sakoda, and Makoto Osaki. 2014. Effect of surface roughness of biomaterials on Staphylococcus epidermidis adhesion. *BMC Microbiology* 14. BioMed Central Ltd.: 1–7. <https://doi.org/10.1186/S12866-014-0234-2/FIGURES/2>.
122. Montanaro, Lucio, Carla Renata Arciola, and Lucilla Baldassarri. 2002. In catheter infections by Staphylococcus epidermidis the intercellular adhesion (ica) locus is a molecular marker of the virulent slime-producing strains. *Journal of biomedical materials research* 59. J Biomed Mater Res: 557–562. <https://doi.org/10.1002/JBM.10006>.
123. Berne, C., C.K. Ellison, A. Ducret, and Y.V. Brun. 2018. Bacterial adhesion at the single-cell level. *Nat Rev Microbiol* 16: 616–627.
124. Boks, N.P., W. Norde, H.C. van der Mei, and H.J. Busscher. 2008. Forces involved in bacterial adhesion to hydrophilic and hydrophobic surfaces. *Microbiology* 154: 3122–3133.
125. Høiby, Niels, Oana Ciofu, Helle Krogh Johansen, Zhi Jun Song, Claus Moser, Peter Østrup Jensen, Søren Molin, Michael Givskov, Tim Tolker-Nielsen, and Thomas Bjørnsholt. 2011. The clinical impact of bacterial biofilms. *International journal of oral science* 3. Int J Oral Sci: 55–65. <https://doi.org/10.4248/IJOS11026>.
126. Arciola, Carla Renata, Davide Campoccia, Stefano Ravaoli, and Lucio Montanaro. 2015. Polysaccharide intercellular adhesin in biofilm: Structural and regulatory aspects. *Frontiers in Cellular and Infection Microbiology* 5. Frontiers Research Foundation. <https://doi.org/10.3389/FCIMB.2015.00007/FULL>.
127. Rumbaugh, K.P., and K. Sauer. 2020. Biofilm dispersion. *Nat Rev Microbiol* 18: 571–586.
128. Costerton, J.W. 1999. Bacterial biofilms: a common cause of persistent infections. *Science* 284: 1318–1322.
129. Vestby, L.K., T. Grønseth, R. Simm, and L.L. Nesse. 2020. Bacterial biofilm and its role in the pathogenesis of disease. *Antibiotics* 9: 1–28.

130. Fey, Paul D., and Michael E. Olson. 2010. Current concepts in biofilm formation of *Staphylococcus epidermidis*. *Future microbiology* 5. NIH Public Access: 917. <https://doi.org/10.2217/FMB.10.56>.
131. Pajkos, Aniko, Anand K. Deva, Karen Vickery, Charles Cope, Lionel Chang, and Yvonne E. Cossart. 2003. Detection of subclinical infection in significant breast implant capsules. *Plastic and reconstructive surgery* 111. *Plast Reconstr Surg*: 1605–1611. <https://doi.org/10.1097/01.PRS.0000054768.14922.44>.
132. Sopwith, Will, Tony Hart, and Paul Garner. 2002. Preventing infection from reusable medical equipment: a systematic review. *BMC infectious diseases* 2. *BMC Infect Dis*. <https://doi.org/10.1186/1471-2334-2-4>.
133. F, Biron, Verrier B, and Peyramond D. 1997. Transmission of the human immunodeficiency virus and the hepatitis C virus. *The New England journal of medicine* 337. *N Engl J Med*: 348–349. <https://doi.org/10.1056/NEJM199707313370515>.
134. Gillespie, T. G., L. Hogg, E. Budge, A. Duncan, and J. E. Coia. 2000. *Mycobacterium chelonae* isolated from rinse water within an endoscope washer-disinfector. *The Journal of hospital infection* 45. *J Hosp Infect*: 332–334. <https://doi.org/10.1053/JHIN.2000.0782>.
135. Schelenz, S., and G. French. 2000. An outbreak of multidrug-resistant *Pseudomonas aeruginosa* infection associated with contamination of bronchoscopes and an endoscope washer-disinfector. *The Journal of hospital infection* 46. *J Hosp Infect*: 23–30. <https://doi.org/10.1053/JHIN.2000.0800>.
136. Srinivasan, Arjun, Linda L. Wolfenden, Xiaoyan Song, Karen Mackie, Theresa L. Hartsell, Heather D. Jones, Gregory B. Diette, et al. 2003. An outbreak of *Pseudomonas aeruginosa* infections associated with flexible bronchoscopes. *The New England journal of medicine* 348. *N Engl J Med*: 221–227. <https://doi.org/10.1056/NEJMOA021808>.
137. Cohen, Justin B., Cathy Carroll, Marissa M. Tenenbaum, and Terence M. Myckatyn. 2015. Breast implant-associated infections: The role of the national surgical quality improvement program and the local microbiome. *Plastic and Reconstructive Surgery* 136. <https://doi.org/10.1097/PRS.0000000000001682>.
138. Palubicka, Anna, Radoslaw Jaworski, Marcin Wekwejt, Beata Swieczko-Zurek, Michal Pikula, Janusz Jaskiewicz, and Jacek Zielinski. 2019. Surgical site infection after breast surgery: A retrospective analysis of 5-year postoperative data from a single center in Poland. *Medicina (Lithuania)* 55. <https://doi.org/10.3390/medicina55090512>.
139. Prantl, Lukas, Arash Momeni, Vanessa Brebant, Britta Kuehlmann, Norbert Heine, Niklas Biermann, and Eva Brix. 2020. Recommendations for the Use of Antibiotics in Primary and Secondary Esthetic Breast Surgery. *Plastic and Reconstructive Surgery - Global Open* 8. <https://doi.org/10.1097/GOX.0000000000002590>.
140. Yalanis, Georgia C., En Wei Liu, and Hsu Tang Cheng. 2015. Efficacy and safety of povidone-iodine irrigation in reducing the risk of capsular contracture in aesthetic breast augmentation: A systematic review and meta-analysis. *Plastic and Reconstructive Surgery*. <https://doi.org/10.1097/PRS.0000000000001576>.
141. Burkhardt, B. R., P. D. Dempsey, P. L. Schnur, and J. J. Tofield. 1986. Capsular contracture: A prospective study of the effect of local antibacterial agents. *Plastic and Reconstructive Surgery* 77. <https://doi.org/10.1097/00006534-198606000-00008>.
142. Brandon, Harold J., V. Leroy Young, Kenneth L. Jerina, Clarence J. Wolf, William P. Adams, and Maria E. Watson. 2002. Mechanical analysis of explanted saline-filled breast implants exposed to betadine pocket irrigation. *Aesthetic Surgery Journal* 22. <https://doi.org/10.1067/maj.2002.128626>.
143. U.S. Food and Drug Administration (2017). 2023. Premarket Approval (PMA). <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=402786>. Accessed October 30.
144. Adams, Jr, W. C.H. Conner, Jr Barton, and R. J. Rohrich. 2001. Optimizing breast-pocket irrigation: The post-Betadine era. *Plastic and Reconstructive Surgery* 107. <https://doi.org/10.1097/00006534-200105000-00049>.
145. Jewell, Mark L., and William P. Adams. 2018. Betadine and Breast Implants. *Aesthetic Surgery Journal* 38. <https://doi.org/10.1093/asj/sjy044>.
146. Adams, William P. 2018. Commentary on: Surgical Site Irrigation in Plastic Surgery: What is Essential? *Aesthetic Surgery Journal*. <https://doi.org/10.1093/asj/sjx214>.
147. Viola, George M., Kenneth V. Rolston, Charles Butler, Jesse Selber, Gregory Reece, Mark Clemens, Mark Villa, Issam I. Raad, and Donald Baumann. 2019. Evaluation of Current Perioperative Antimicrobial Regimens for the Prevention of Surgical Site Infections in Breast Implant-based Reconstructive Surgeries. In *Plastic and Reconstructive Surgery - Global Open*. Vol. 7. <https://doi.org/10.1097/GOX.0000000000002342>.
148. Zhadan, Olga, and Hilton Becker. 2018. Surgical Site Irrigation in Plastic Surgery. *Aesthetic surgery journal* 38. *Aesthet Surg J*: 265–273. <https://doi.org/10.1093/ASJ/SJX171>.
149. McKinnon, P. S., and S. L. Davis. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology* 23. *Eur J Clin Microbiol Infect Dis*: 271–288. <https://doi.org/10.1007/S10096-004-1107-7>.
150. Scuderi, Nicolò, Marco Mazzocchi, Paolo Fioramonti, and Giovanni Bistoni. 2006. The effects of zafirlukast on capsular contracture: Preliminary report. *Aesthetic Plastic Surgery* 30. <https://doi.org/10.1007/s00266-006-0038-3>.

151. Abbinante, Giulia, Sergio Brongo, Domenico Pagliara, Roberto Cuomo, Giulia Abbinante, Nicola Campitiello, Fabio Santanelli, and Daniela Chessa. 2014. Infections in breast implants: A review with a focus on developing countries. *Journal of Infection in Developing Countries*. <https://doi.org/10.3855/jdc.3898>.
152. Jianu, Dana Mihaela, Oana Săndulescu, Anca Streinu-Cercel, Ioana Berciu, Alexandru Blidaru, Maria Filipescu, Mihaela Vartic, et al. 2015. Microbiologic Safety of the Transareolar Approach in Breast Augmentation. *Aesthetic Surgery Journal* 36. <https://doi.org/10.1093/asj/sjv106>.
153. Zhang, Hanwen, Yang Wang, Shuang Yang, and Yan Zhang. 2020. Peri-operative antibiotic prophylaxis does not reduce surgical site infection in breast cancer. *Surgical Infections* 21. <https://doi.org/10.1089/sur.2019.116>.
154. Monroig, Kaitlin, Kanad Ghosh, Jocellie E. Marquez, Christopher Medrano, William A. Marmor, Phoebe McAuliffe, Austin Ferrier, et al. 2020. Do Postoperative Prophylactic Antibiotics Reduce Highly Virulent Infections?: An Analysis of 660 Tissue Expander Breast Reconstructions. *Annals of Plastic Surgery* 85. <https://doi.org/10.1097/SAP.0000000000002325>.
155. Gil Conesa, M., N. M. Climent Martínez, Juan Antonio Del Moral Luque, M. Durán Poveda, D. Rodríguez Villar, and G. Rodríguez Caravaca. 2019. Evaluation of compliance with the antibiotic prophylaxis protocol in breast surgery and its effect on the incidence of surgical infection. *Anales del Sistema Sanitario de Navarra* 42. <https://doi.org/10.23938/ASSN.0637>.
156. Doherty, Chris, J. Andrew McClure, Nancy N. Baxter, and Muriel Brackstone. 2023. Complications From Postmastectomy Radiation Therapy in Patients Undergoing Immediate Breast Reconstruction: A Population-Based Study. *Advances in Radiation Oncology* 8. <https://doi.org/10.1016/j.adro.2022.101104>.
157. Adams, William P., Eric J. Culbertson, Anand K. Deva, Mark R. Magnusson, Craig Layt, Mark L. Jewell, Patrick Mallucci, and Per Hedén. 2017. Macrot textured breast implants with defined steps to minimize bacterial contamination around the device: Experience in 42,000 implants. *Plastic and Reconstructive Surgery* 140. <https://doi.org/10.1097/PRS.0000000000003575>.
158. Hu, Honghua, Janine Sleiman, Khalid Johani, and Karen Vickery. 2018. Hypochlorous acid versus povidone-iodine containing irrigants: Which antiseptic is more effective for breast implant pocket irrigation? *Aesthetic Surgery Journal* 38. <https://doi.org/10.1093/asj/sjx213>.
159. Brody, G. S. 1997. On the safety of breast implants. *Plastic and Reconstructive Surgery*. <https://doi.org/10.1097/00006534-199710000-00039>.
160. Steiert, Andreas E., Maria Boyce, and Heiko Sorg. 2013. Capsular contracture by silicone breast implants: Possible causes, biocompatibility, and prophylactic strategies. *Medical Devices: Evidence and Research* 6: 211–218. <https://doi.org/10.2147/MDER.S49522>.
161. Risks and Complications of Breast Implants | FDA. 2022. <https://www.fda.gov/medical-devices/breast-implants/risks-and-complications-breast-implants>. Accessed November 21.
162. Jewell, Mark L., Bradley P. Bengtson, Kate Smither, Gina Nuti, and Tracyann Perry. 2019. Physical properties of silicone gel breast implants. *Aesthetic Surgery Journal* 39. <https://doi.org/10.1093/asj/sjy103>.
163. Henriksen, Trine F., Jon P. Fryzek, Lisbet R. Hölmich, Joseph K. McLaughlin, Kim Kjoller, Annette Pernille Høyer, Jørgen H. Olsen, and Søren Friis. 2005. Surgical intervention and capsular contracture after breast augmentation: A prospective study of risk factors. *Annals of Plastic Surgery* 54. <https://doi.org/10.1097/01.sap.0000151459.07978.fa>.
164. Namnoum, James D., Joan Largent, Hilton M. Kaplan, Michael G. Oefelein, and Mitchell H. Brown. 2013. Primary breast augmentation clinical trial outcomes stratified by surgical incision, anatomical placement and implant device type. *Journal of plastic, reconstructive & aesthetic surgery: JPRAS* 66. J Plast Reconstr Aesthet Surg: 1165–1172. <https://doi.org/10.1016/J.BJPS.2013.04.046>.
165. Moyer, HR, B Ghazi, A Losken - Plastic and Reconstructive Surgery, and undefined 2011. 2024. Sterility in breast implant placement: the Keller funnel and the “no touch” technique. *journals.lww.comHR Moyer, B Ghazi, A LoskenPlastic and Reconstructive Surgery, 2011•journals.lww.com.* [https://journals.lww.com/plasreconsurg/fulltext/2011/10001/Capsular\\_Contracture\\_Rate\\_in\\_Low\\_Risk\\_Population.14.aspx](https://journals.lww.com/plasreconsurg/fulltext/2011/10001/Capsular_Contracture_Rate_in_Low_Risk_Population.14.aspx). Accessed August 27.
166. Vazquez, Bernabe, Kenna S. Given, and G. Courtney Houston. 1987. Breast augmentation: a review of subglandular and submuscular implantation. *Aesthetic plastic surgery* 11. *Aesthetic Plast Surg*: 101–105. <https://doi.org/10.1007/BF01575494>.
167. Wong, Chin Ho, Miny Samuel, Bien Keem Tan, and Colin Song. 2006. Capsular contracture in subglandular breast augmentation with textured versus smooth breast implants: a systematic review. *Plastic and reconstructive surgery* 118. *Plast Reconstr Surg*: 1224–1236. <https://doi.org/10.1097/01.PRS.0000237013.50283.D2>.
168. Khandwekar, Anand, and Cho K. Rho. 2012. Modulation of cellular responses on engineered polyurethane implants. *Journal of Biomedical Materials Research - Part A* 100 A: 2211–2222. <https://doi.org/10.1002/JBM.A.34146>.
169. Manav, Safa, M. Sühan Ayhan, Erkan Deniz, Esra Özkoçer, Çiğdem Elmas, Meltem Yalinay, and Erdem Şahin. 2020. Capsular contracture around silicone miniimplants following bacterial contamination: an in



- vivo comparative experimental study between textured and polyurethane implants. *Journal of Plastic, Reconstructive and Aesthetic Surgery* 73. <https://doi.org/10.1016/j.bjps.2020.02.049>.
170. Duxbury, Paula J., and James R. Harvey. 2016. Systematic review of the effectiveness of polyurethane-coated compared with textured silicone implants in breast surgery. *Journal of Plastic, Reconstructive and Aesthetic Surgery*. <https://doi.org/10.1016/j.bjps.2016.01.013>.
  171. Daka, Joseph N., and Attar S. Chawla. 1993. Release of chemicals from polyurethane foam in the Mème breast implant. *Biomaterials, artificial cells, and immobilization biotechnology: official journal of the International Society for Artificial Cells and Immobilization Biotechnology* 21. *Biomater Artif Cells Immobilization Biotechnol*: 23–46. <https://doi.org/10.3109/10731199309118294>.
  172. Harmeling, J. X., Kevin Peter Cinca, Eleni Rosalina Andrinopoulou, Eveline M.L. Corten, and M. A. Mureau. 2021. Long-term outcomes of two-stage, immediate and delayed breast reconstruction with polyurethane-covered versus textured implants: protocol of a prospective, multicentre randomised controlled trial (TIPI trial). *BMJ open* 11. *BMJ Open*. <https://doi.org/10.1136/BMJOPEN-2020-044219>.
  173. Encinas, Noemí, Ching Yu Yang, Florian Geyer, Anke Kaltbeitzel, Philipp Baumli, Jonas Reinholz, Volker Mailänder, Hans Jürgen Butt, and Doris Vollmer. 2020. Submicrometer-Sized Roughness Suppresses Bacteria Adhesion. *ACS Applied Materials and Interfaces* 12. American Chemical Society: 21192–21200. [https://doi.org/10.1021/ACSAMI.9B22621/ASSET/IMAGES/LARGE/AM9B22621\\_0005.JPEG](https://doi.org/10.1021/ACSAMI.9B22621/ASSET/IMAGES/LARGE/AM9B22621_0005.JPEG).
  174. Alessandri-Bonetti, Mario, Tiffany Jeong, Luca Vailenti, Carolyn De La Cruz, Michael L Gimbel, Vu T Nguyen, and Francesco M Egro. 2023. The Role of Microorganisms in the Development of Breast Implant-Associated Anaplastic Large Cell Lymphoma. *Pathogens (Basel, Switzerland)* 12. MDPI. <https://doi.org/10.3390/pathogens12020313>.
  175. Rolph, Rachel, and Jian Farhadi. 2018. The use of meshes and matrices in breast reconstruction. *British journal of hospital medicine (London, England: 2005)* 79. NLM (Medline): 454–459. <https://doi.org/10.12968/HMED.2018.79.8.454>.
  176. Jacombs, Anita, James Allan, Honghua Hu, Pedro Miguel Valente, William L.F. Wessels, Anand K. Deva, and Karen Vickery. 2012. Prevention of biofilm-induced capsular contracture with antibiotic-impregnated mesh in a porcine model. *Aesthetic surgery journal* 32. *Aesthet Surg J*: 886–891. <https://doi.org/10.1177/1090820X12455429>.
  177. Ruff, Eric S., Takashi Hirase, and Malcolm J. Rude. 2019. Evaluation of antibiotic-impregnated mesh in preventing the recurrence of capsular contracture. *Aesthetic Surgery Journal* 39. Oxford University Press: 509–515. <https://doi.org/10.1093/asj/sjy171>.
  178. Borkner, Christian B., Stefanie Wohlrab, Eva Möller, Gregor Lang, and Thomas Scheibel. 2017. Surface Modification of Polymeric Biomaterials Using Recombinant Spider Silk Proteins. *ACS Biomaterials Science and Engineering* 3. American Chemical Society: 767–775. <https://doi.org/10.1021/acsbmaterials.6b00306>.
  179. Weiss, Alessia C.G., Heike M. Herold, Sarah Lentz, Matthew Faria, Matthew Faria, Quinn A. Besford, Ching Seng Ang, et al. 2020. Surface Modification of Spider Silk Particles to Direct Biomolecular Corona Formation. *ACS Applied Materials and Interfaces* 12. <https://doi.org/10.1021/acsami.0c06344>.
  180. Salehi, Sahar, Kim Koeck, and Thomas Scheibel. 2020. Spider silk for tissue engineering applications. *Molecules*. <https://doi.org/10.3390/molecules25030737>.
  181. Scheibel, Thomas. 2004. Spider silks: Recombinant synthesis, assembly, spinning, and engineering of synthetic proteins. *Microbial Cell Factories*. <https://doi.org/10.1186/1475-2859-3-14>.
  182. Kumari, Sushma, Gregor Lang, Elise DeSimone, Christian Spengler, Vanessa T. Trossmann, Susanne Lückner, Martina Hudel, Karin Jacobs, Norbert Krämer, and Thomas Scheibel. 2020. Engineered spider silk-based 2D and 3D materials prevent microbial infestation. *Materials Today*. Elsevier B.V. <https://doi.org/10.1016/j.mattod.2020.06.009>.
  183. Kumari, Sushma, Hendrik Bargel, and Thomas Scheibel. 2020. Recombinant Spider Silk–Silica Hybrid Scaffolds with Drug-Releasing Properties for Tissue Engineering Applications. *Macromolecular Rapid Communications* 41. <https://doi.org/10.1002/marc.201900426>.
  184. Zeplin, Philip H., Nathalie C. Maksimovikj, Martin C. Jordan, Joachim Nickel, Gregor Lang, Axel H. Leimer, Lin Römer, and Thomas Scheibel. 2014. Spider silk coatings as a bioshield to reduce periprosthetic fibrous capsule formation. *Advanced Functional Materials* 24. <https://doi.org/10.1002/adfm.201302813>.
  185. Erathodiyil, Nandan, Hsi Min Chan, Hong Wu, and Jackie Y. Ying. 2020. Zwitterionic polymers and hydrogels for antibiofouling applications in implantable devices. *Materials Today* 38. Elsevier: 84–98. <https://doi.org/10.1016/J.MATTOD.2020.03.024>.
  186. Mi, Luo, and Shaoyi Jiang. 2014. Integrated antimicrobial and nonfouling zwitterionic polymers. *Angewandte Chemie - International Edition* 53: 1746–1754. <https://doi.org/10.1002/anie.201304060>.
  187. Li, Bowen, Zhefan Yuan, Priyesh Jain, Hsiang Chieh Hung, Yuwei He, Xiaojie Lin, Patrick McMullen, and Shaoyi Jiang. 2020. De novo design of functional zwitterionic biomimetic material for immunomodulation. *Science advances* 6. *Sci Adv*. <https://doi.org/10.1126/SCIADV.ABA0754>.

188. Zhang, Lei, Zhiqiang Cao, Tao Bai, Louisa Carr, Jean Rene Ella-Menye, Colleen Irvin, Buddy D. Ratner, and Shaoyi Jiang. 2013. Zwitterionic hydrogels implanted in mice resist the foreign-body reaction. *Nature biotechnology* 31. Nat Biotechnol: 553–556. <https://doi.org/10.1038/NBT.2580>.
189. Li, Bowen, Priyesh Jain, Jinrong Ma, Josh K. Smith, Zhefan Yuan, Hsiang Chieh Hung, Yuwei He, et al. 2019. Trimethylamine N-oxide-derived zwitterionic polymers: A new class of ultralow fouling bioinspired materials. *Science Advances* 5. American Association for the Advancement of Science. <https://doi.org/10.1126/sciadv.aaw9562>.
190. Jansen, Lauren E., Luke D. Amer, Esther Y.T. Chen, Thuy V. Nguyen, Leila S. Saleh, Todd Emrick, Wendy F. Liu, Stephanie J. Bryant, and Shelly R. Peyton. 2018. Zwitterionic PEG-PC Hydrogels Modulate the Foreign Body Response in a Modulus-Dependent Manner. *Biomacromolecules* 19. Biomacromolecules: 2880–2888. <https://doi.org/10.1021/ACS.BIOMAC.8B00444>.
191. Adams, William P., Jose L. Rios, and Sharon J. Smith. 2006. Enhancing patient outcomes in aesthetic and reconstructive breast surgery using triple antibiotic breast irrigation: Six-year prospective clinical study. *Plastic and Reconstructive Surgery* 117. <https://doi.org/10.1097/01.prs.0000185671.51993.7e>.
192. Giordano, Salvatore, Hilkka Peltoniemi, Peter Lilius, and Asko Salmi. 2013. Povidone-iodine combined with antibiotic topical irrigation to reduce capsular contracture in cosmetic breast augmentation: a comparative study. *Aesthetic surgery journal* 33. Aesthet Surg J: 675–680. <https://doi.org/10.1177/1090820X13491490>.
193. Drinane, James J., Ronald S. Bergman, Bryan L. Folkers, and Matthew J. Kortes. 2013. Revisiting triple antibiotic irrigation of breast implant pockets: A placebo-controlled single practice cohort study. *Plastic and Reconstructive Surgery - Global Open* 1. Lippincott Williams and Wilkins. <https://doi.org/10.1097/GOX.0B013E3182AA8760>.
194. Jewell, Mark L., Sara Hariri, Ellen E. Lantz, Hillary L. Jewell, Aaron D. Strickland, and Braden K. Leung. 2021. In Vitro Evaluation of Common Antimicrobial Solutions Used for Breast Implant Soaking and Breast Pocket Irrigation—Part 1: Efficacy Against Planktonic Bacteria. *Aesthetic Surgery Journal* 41. Oxford Academic: 1242–1251. <https://doi.org/10.1093/ASJ/SJAA309>.
195. Baker, Jennifer E., Aaron P. Seitz, Ryan M. Boudreau, Mitchell J. Skinner, Ahmed Beydoun, Necati Kaval, Charles C. Caldwell, Erich Gulbins, Michael J. Edwards, and Ryan M. Gobble. 2020. Doxycycline-Coated Silicone Breast Implants Reduce Acute Surgical-Site Infection and Inflammation. *Plastic and Reconstructive Surgery* 146. Lippincott Williams and Wilkins: 1029–1041. <https://doi.org/10.1097/PRS.0000000000007277>.
196. Nguyen, Lyly, Ashkan Afshari, Japit Green, Jeremy Joseph, Jun Yao, Galen Perdakis, and Kent K. Higdon. 2021. Post-Mastectomy Surgical Pocket Irrigation With Triple Antibiotic Solution vs Chlorhexidine Gluconate: A Randomized Controlled Trial Assessing Surgical Site Infections in Immediate Tissue Expander Breast Reconstruction. *Aesthetic surgery journal* 41. Aesthet Surg J: NP1521–NP1528. <https://doi.org/10.1093/ASJ/SJAB290>.
197. Unlu, Ramazan Erkin, Asu Deniz Yilmaz, Hakan Orbay, Belgin Can, Ibrahim Tekdemir, and Omer Sensoz. 2007. Influence of rifampin on capsule formation around silicone implants in a rat model. *Aesthetic plastic surgery* 31. Aesthetic Plast Surg: 358–364. <https://doi.org/10.1007/S00266-006-0248-8>.
198. Gancedo, Matias, Luis Ruiz-Corro, Adriana Salazar-Montes, Ana Rosa Rincón, and Juan Armendáriz-Borunda. 2008. Pirfenidone prevents capsular contracture after mammary implantation. *Aesthetic plastic surgery* 32. Aesthetic Plast Surg: 32–40. <https://doi.org/10.1007/S00266-007-9051-4>.
199. Schaefer, C. J., D. W. Ruhmund, L. Pan, S. D. Seiwert, and K. Kossen. 2011. Antifibrotic activities of pirfenidone in animal models. *European respiratory review : an official journal of the European Respiratory Society* 20. Eur Respir Rev: 85–97. <https://doi.org/10.1183/09059180.00001111>.
200. Fayzullin, Alexey, Semyon Churbanov, Natalia Ignatieva, Olga Zakharkina, Mark Tokarev, Daniil Mudryak, Yana Khristidis, et al. 2021. Local Delivery of Pirfenidone by PLA Implants Modifies Foreign Body Reaction and Prevents Fibrosis. *Biomedicines* 9. Biomedicines. <https://doi.org/10.3390/BIOMEDICINES9080853>.
201. Grattendick, K. J., J. M. Nakashima, L. Feng, S. N. Giri, and S. B. Margolin. 2008. Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro. *International immunopharmacology* 8. Int Immunopharmacol: 679–687. <https://doi.org/10.1016/J.INTIMP.2008.01.013>.
202. Zeplin, Philip H., Axel Larena-Avellaneda, and Karsten Schmidt. 2010. Surface modification of silicone breast implants by binding the antifibrotic drug halofuginone reduces capsular fibrosis. *Plastic and reconstructive surgery* 126. Plast Reconstr Surg: 266–274. <https://doi.org/10.1097/PRS.0B013E3181DBC313>.
203. Pines, M., and A. Nagler. 1998. Halofuginone: A novel antifibrotic therapy. *General Pharmacology* 30. Gen Pharmacol: 445–450. [https://doi.org/10.1016/S0306-3623\(97\)00307-8](https://doi.org/10.1016/S0306-3623(97)00307-8).
204. Granot, I., O. Halevy, S. Hurwitz, and M. Pines. 1993. Halofuginone: an inhibitor of collagen type I synthesis. *Biochimica et biophysica acta* 1156. Biochim Biophys Acta: 107–112. [https://doi.org/10.1016/0304-4165\(93\)90123-P](https://doi.org/10.1016/0304-4165(93)90123-P).



205. McGaha, Tracy L., Robert G. Phelps, Harry Spiera, and Constantin Bona. 2002. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. *The Journal of investigative dermatology* 118. J Invest Dermatol: 461–470. <https://doi.org/10.1046/J.0022-202X.2001.01690.X>.
206. Guimier, Eugénie, Louise Carson, Benny David, James M. Lambert, Enda Heery, and R. Karl Malcolm. 2022. Pharmacological Approaches for the Prevention of Breast Implant Capsular Contracture. *Journal of Surgical Research* 280. Elsevier: 129–150. <https://doi.org/10.1016/J.JSS.2022.06.073>.
207. Colak, Ozlem, Kadri Ozer, Adile Dikmen, Hilal Ozakinci, and Ozay Ozkaya. 2018. Evaluation of Safe Systemic Immunosuppression Created with Dexamethasone in Prevention of Capsular Contracture: A Glance to Distinct Perspectives with Toll-Like Receptors. *Aesthetic plastic surgery* 42. Aesthetic Plast Surg: 1133–1143. <https://doi.org/10.1007/S00266-018-1119-9>.
208. Wilk, Maciej, Roland Hessler, Kenneth Mugridge, Claude Jolly, Michael Fehr, Thomas Lenarz, and Verena Scheper. 2016. Impedance Changes and Fibrous Tissue Growth after Cochlear Implantation Are Correlated and Can Be Reduced Using a Dexamethasone Eluting Electrode. *PloS one* 11. PLoS One. <https://doi.org/10.1371/JOURNAL.PONE.0147552>.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.